

Prof. YUSUF YILMAZ

Personal Information

Email: yusuf.yilmaz@erdogan.edu.tr

Other Email: dryusufyilmaz@gmail.com

Web: <https://avesis.erdogan.edu.tr/yusuf.yilmaz>

International Researcher IDs

ScholarID: -xUdXf8AAAAJ

ORCID: 0000-0003-4518-5283

Publons / Web Of Science ResearcherID: K-6651-2012

ScopusID: 22936014300

Yoksis Researcher ID: 187733

Biography

1978 yılında Rize'de doğan Yusuf Yılmaz 1996 yılında İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi'ni kazanarak dereceyle mezun olma başarısını göstererek 2002 yılında 'Tıp Doktoru' ünvanını almıştır. Aynı yıl tıpta uzmanlık sınavını kazanarak Uludağ Üniversitesi Tıp Fakültesi'ne girmiştir, 2007 yılında 'İç Hastalıkları Uzmanı' olmuştur. Kısa bir süre zorunlu hizmet görevini yerine getirerek 2008 yılında kazandığı yan dal sınavı ile Marmara Üniversitesi Tıp Fakültesi Gastroenteroloji Bilim Dalı'nda yan dal uzmanlık eğitimi başlamıştır. 2011 yılında 'Gastroenteroloji Uzmanı' da olan ve aynı yıl Doçentlik sınavını da başarıyla veren Yusuf Yılmaz 2012 yılında Marmara Üniversitesi Tıp Fakültesi'ne 'Öğretim Üyesi' olarak atanmıştır. 2017 yılında tıp fakültesine atanın en genç 'Profesör' olmuştur. 2018 yılında dünyada 'Tıp Bilimine Yön Veren 100 Türk' arasına girmiştir.

Prof. Dr. Yusuf Yılmaz'ın uluslararası yabancı dergilerde yayımlanmış 150'ye yakın bilimsel araştırması bulunmaktadır. Uluslararası bir kuruluş olan Webometrics 2016 verilerine göre Dr. Yusuf Yılmaz, Türkiye'deki tüm bilim insanları içerisinde (sadece tıp alanında değil) 223. sıraya yerleşme başarısına bu genç yaşında ulaşmıştır. Google Akademik 2018 verilerine göre >30 h endeksi ve 4000 alıntılanma sayısı ile ülkemizin en iyi akademisyenleri arasında gösterilmektedir.

Yüksek özverili çalışmaları sayesinde alanında sadece dünyaca ünlü bilim insanların davet edilerek derlemelerinin yayımlandığı prestijli dergilerde yazar olma başarısını göstermiştir. Bütün bu başarılar sayesinde uluslararası NASH komitesine seçilen Avrupa'dan sayılı birkaç bilim insanından biridir. Ayrıca Avrupa Karaciğer Araştırmaları Derneği, Amerikan Karaciğer Araştırmaları Derneği, Amerikan Kronik Karaciğer Vakfı üyeliği bulunmaktadır.

Hepatology, Journal of Hepatology, Alimentary Pharmacology and Therapeutics, Diabetes Care , Metabolism gibi 50'den fazla uluslararası dergide hakemlik görevi bulunmaktadır. Çeşitli yıllarda en iyi hakem, en fazla alıntı yapılan araştırma, en çok alıntı yapılan derleme sahibi bilim insanı başarısını da göstermiştir.

Türkiye'de Fibroscan kullanımında en deneyimli kişi olan Prof. Dr. Yusuf Yılmaz, bu deneyimini gerek yurt içinde gerekse yurt dışında hekimlere yönelik eğitim kurslarıyla meslektaşlarıyla paylaşmaktadır.

Education

Post Doctorate of Medicine, Marmara University, School Of Medicine, Turkey 2008 - 2011

Expertise In Medicine, Uludağ Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2002 - 2007

Undergraduate, İstanbul University, Cerrahpaşa Tıp Fakültesi, Turkey 1996 - 2002

Foreign Languages

English, C1 Advanced

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases , Gastroenterology and Hepatology

Academic Positions

Professor, Marmara University, School Of Medicine, Internal Medical Sciences, 2017 - Present

Academic and Administrative Experience

Rector, Recep Tayyip Erdogan University, Rektörlük, 2022 - Present

Director of The Institution, Marmara University, Institute Of Gastroenterology, 2014 - 2022

Supervised Theses

- Yılmaz Y., OBEZ HASTALARDA KARACİĞER YAĞLANMASININ VE FİBROZİSİNİN FİBROSCAN İLE NONINVAZİV OLARAK DEĞERLENDİRİLMESİ, Expertise In Medicine, A.AVCU(Student), 2020
- Yılmaz Y., Biyopsi kanıtlı non-alkolik yağlı karaciğer hastalığı bulunan bireylerde tip 2 diabetes mellitus, metabolik sendrom ve obezite prevalansının değerlendirilmesi, Expertise In Medicine, H.JAFAROVA(Student), 2019
- Yılmaz Y., Nonalkolik karaciğer yağlanması bulunan hastalarda aterosklerozun ve karaciğer sertliğinin noninvazif değerlendirilmesi, Expertise In Medicine, B.Ören(Student), 2019
- Güneş F. E., Yılmaz Y., Alkolik olmayan karaciğer yağlanması olan hastalarda bağırsaktaki faecalibacterium prausnitzii ve eubacterium rectale bakterilerinin değişimlerinin uygulanan diyet modeli ile ilişkilendirilmesi, Postgraduate, E.OĞUZ(Student), 2019
- Yılmaz Y., Fibroscan'in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.JAFAROV(Student), 2019
- Yılmaz Y., Fibroscan'in nonalkolik yağlı karaciğer hastalığındaki tanısal performansının değerlendirilmesi, Expertise In Medicine, F.Jafarov(Student), 2019
- Tüfekçi Alphan M. E., Yılmaz Y., Normal kilolu non-alkolik yağlı karaciğer hastalığı olan bireylerde tıbbi beslenme tedavisinin etkinliğinin değerlendirilmesi, Doctorate, P.HAMURCU(Student), 2018
- Yılmaz Y., Tip 2 diyabetli hastalarda karaciğer sertliğinin ve yağlanması Fibroscan ile saptanması, Expertise In Medicine, M.Demir(Student), 2018
- YILMAZ Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometer VCTE'nin tanısal performansı, Expertise In Medicine, E.Dinçses(Student), 2015
- Yılmaz Y., Non-alkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında non-invaziv fibrozis testlerinin tanısal performansı, Expertise In Medicine, C.FIRAT(Student), 2015
- Yılmaz Y., Nonalkolik yağlı karaciğerli hastalarda ileri evre fibrozisin saptanmasında noninvaziv yeni bir yöntem olan fibrometer VCTE'nin tanısal performansı, Expertise In Medicine, E.DİNÇSES(Student), 2015
- Yılmaz Y., Nonalkolik yağlı karaciğer hastalığında fibrozisin noninvaziv yöntemlerle araştırılması, Expertise In Medicine, U.EMRE(Student), 2014

Jury Memberships

Journal articles indexed in SCI, SSCI, and AHCI

- I. **Resmetirom-eligible population among US adults: An estimation analysis based on NHANES 2017-March 2020.**
Le P., Kaya E., Phan A., Yilmaz Y., Alkhouri N.
Hepatology communications, vol.9, no.7, 2025 (SCI-Expanded)
- II. **Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry**
YILMAZ Y., Keklikkiran Ç., Racila A., Stepanova M., Younossi Z.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, vol.16, no.6, 2025 (SCI-Expanded)
- III. **Metabolic Dysfunction-Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda**
El-Kassas M., Alswat K. A., Yilmaz Y., Labidi A., Sanai F. M., Awad A., Alqahtani S. A., Elbadry M., Abdeen N., Henry L., et al.
LIVER INTERNATIONAL, vol.45, no.6, 2025 (SCI-Expanded)
- IV. **Clinical Insights on Resmetirom: Clinical Indications, Patient Selection, and Monitoring Response to Therapy.**
Kaya E., Yilmaz Y., Alkhouri N.
Journal of clinical gastroenterology, vol.59, no.5, pp.412-419, 2025 (SCI-Expanded)
- V. **Hepatocellular carcinoma in the MENA region differs in presentation and outcomes: an analysis of 2736 patients from Saudi Arabia, Oman, Egypt and Turkiye**
Sanai F. M., DEMİRTAŞ C. Ö., Khalid A. N., Alzanbagi A., Elbadry M., Yilmaz Y., Bzeizi K., Alghamdi H., Alsiyabi O., Sulaimani M. T., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- VI. **Performance of chronic liver disease questionnaire-metabolic dysfunction-associated steatohepatitis (CLDQ-MASH) against non-invasive tests**
Younossi Z., Yilmaz Y., Yu M., El-Kassas M., Fernandez M. I. C., Eguchi Y., Papatheodoridis G., Wong V. W., Duseja A. K., Singal A. K., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- VII. **Rising trends in preventable premature MASLD-related deaths: disparities across urban and rural US counties (2011-2021)**
Paik J. M., Paik A., Yilmaz Y., El-Kassas M., Alqahtani S., Younossi Z.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- VIII. **Letter to the Editor: Should NAFLD be automatically relabeled as MASLD?**
Gökçe D. T., YILMAZ Y.
Hepatology, vol.81, no.5, 2025 (SCI-Expanded)
- IX. **In patients with metabolic dysfunction-associated steatotic liver disease, sleep disturbance is highly prevalent and associated with a profound impairment of health-related quality of life**
Younossi Z., Yilmaz Y., Yu M., El-Kassas M., Fernandez M. I. C., Eguchi Y., Papatheodoridis G., Wong V. W., Duseja A. K., Singal A. K., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- X. **Physician perspectives on hepatitis C treatment for women of childbearing age and during pregnancy: results from a global multispecialty survey**
Kushner T., Buti M., Papatheodoridis G., El-Kassas M., Yilmaz Y., Takahashi H., Eguchi Y., Roberts S., Chan W., Yu M., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- XI. **A global survey of practice patterns in the management of hepatitis C virus (HCV)-related fibrosis**
Jacobson I., Papatheodoridis G., Buti M., Kushner T., El-Kassas M., Yilmaz Y., Takahashi H., Eguchi Y., Roberts S., Chan

- W., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- XII. **A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality**
Younossi Z., de Avila L., Petta S., Hagstrom H., Kim S. U., Nakajima A., Crespo J., Castera L., Alkhouri N., Zheng M., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- XIII. **Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo**
Rinella M. E., Abdelmalek M. F., Bugianesi E., Cali A., Castera L., Engebretsen K. A., George J., Chan W., Krarup N., Long M., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- XIV. **Metabolic dysfunction-and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort**
Younossi Z., de Avila L., Petta S., Nakajima A., Crespo J., Kim S. U., Castera L., Zheng M., Tsochatzis E., Trivikrama S. K., et al.
JOURNAL OF HEPATOLOGY, 2025 (SCI-Expanded)
- XV. **Global Burden of Major Chronic Liver Diseases in 2021.**
Feng G., Yilmaz Y., Valenti L., Seto W., Pan C. Q., Méndez-Sánchez N., Ye F., Sookoian S., Targher G., Byrne C. D., et al.
Liver international : official journal of the International Association for the Study of the Liver, vol.45, no.4, 2025
(SCI-Expanded)
- XVI. **Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial**
Karahan T. O., Akyuz E. Y., Karadag D. Y., Yilmaz Y., Eren F.
LIFE-BASEL, no.5, 2025 (SCI-Expanded)
- XVII. **Artificial Intelligence-Based Diets: A Role in the Nutritional Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease?**
Ozlu Karahan T., Kenger E. B., YILMAZ Y.
Journal of Human Nutrition and Dietetics, vol.38, no.2, 2025 (SCI-Expanded)
- XVIII. **Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?**
Yilmaz Y.
Hepatology (Baltimore, Md.), vol.81, no.4, 2025 (SCI-Expanded)
- XIX. **Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease.**
Kaya E., Vilar-Gomez E., Vuppalanchi R., Yilmaz Y.
Annals of hepatology, pp.101907, 2025 (SCI-Expanded)
- XX. **Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1**
Karatas F. N., Keklikkiran Ç., Yilmaz Y., Ay P., Korten V., Sili U.
CURRENT HIV RESEARCH, 2025 (SCI-Expanded)
- XXI. **Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021**
Feng G., Targher G., Byrne C. D., YILMAZ Y., Wai-Sun Wong V., Adithya Lesmana C. R., Adams L. A., Boursier J., Papatheodoridis G., El-Kassas M., et al.
JHEP Reports, vol.7, no.3, 2025 (SCI-Expanded)
- XXII. **Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology**
Ratziu V., Yilmaz Y., Lazas D., Friedman S. L., Lackner C., Behling C., Cummings O. W., Chen L., Petitjean M., Gilgun-Sherki Y., et al.
Hepatology, vol.81, no.3, pp.932-946, 2025 (SCI-Expanded)
- XXIII. **The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.**

- Eslam M., Fan J., Yu M., Wong V. W., Cua I. H., Liu C., Tanwandee T., Gani R., Seto W., Alam S., et al.
Hepatology international, 2025 (SCI-Expanded)
- XXIV. Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters, Fibroblast Growth Factor-21, and Cytokeratin-18.**
- Keskin M., Arsoy H. A., Kara O., Sarandol E., Beyaz A., Koca N., Yilmaz Y.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.36, no.3, pp.152-161, 2025 (SCI-Expanded)
- XXV. Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis.**
- Eruzun H., Bossen L., Turan Gökçe D., Ergenç İ., Harput Z. N., Aydemir N. G., Akdoğan Kayhan M., Yapıcı H. B., Doğan T., Holland-Fischer P., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.36, no.4, pp.241-246, 2025 (SCI-Expanded)
- XXVI. Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region**
- Alqahtani S. A., YILMAZ Y., El-Kassas M., Alswat K., Mawardi M., Sanai F. M., Abaakhail F., Alghamdi S., Al-Hamoudi W. K., Nader F., et al.
Annals of Hepatology, vol.30, no.1, 2025 (SCI-Expanded)
- XXVII. Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021**
- Wu C., Targher G., Byrne C. D., Mao Y., Cheung T. T., YILMAZ Y., Valenti L., Méndez-Sánchez N., Sookoian S., Chan W., et al.
American Journal of Gastroenterology, 2025 (SCI-Expanded)
- XXVIII. Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver**
- Çebi M., Yilmaz Y.
FRONTIERS IN IMMUNOLOGY, vol.16, 2025 (SCI-Expanded)
- XXIX. Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease**
- Jiang M., Alqahtani S. A., Seto W., YILMAZ Y., Pan Z., Valenti L., Eslam M.
GASTROENTEROLOGY REPORT, vol.13, 2025 (SCI-Expanded)
- XXX. The MAFLD definition identifies three homogenous groups of patients**
- Pan Z., YILMAZ Y., Al-Busafi S. A., Eslam M.
Liver International, vol.44, no.12, pp.3287-3289, 2024 (SCI-Expanded)
- XXXI. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals**
- Au K., Zheng M., Lee W., Ghanem O. M., Mahawar K., Shabbir A., le Roux C. W., Targher G., Byrne C. D., YILMAZ Y., et al.
Current Obesity Reports, vol.13, no.4, pp.818-830, 2024 (SCI-Expanded)
- XXXII. Letter: Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Biliary Cholangitis—Friend, Foe or Red Herring?**
- Ergenc I., YILMAZ Y.
Alimentary Pharmacology and Therapeutics, vol.60, no.11-12, pp.1641-1642, 2024 (SCI-Expanded)
- XXXIII. Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated Steatotic Liver Disease**
- YILMAZ Y.
Molecular Nutrition and Food Research, vol.68, no.23, 2024 (SCI-Expanded)
- XXXIV. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus.**
- Zeng X., Varady K. A., Wang X., Targher G., Byrne C. D., Tayyem R., Latella G., Bergheim I., Valenzuela R., George J., et al.

- Metabolism: clinical and experimental, vol.161, pp.156028, 2024 (SCI-Expanded)
- XXXV. **Impact of the MetALD terminology on the prevalence of alcohol-related fatty liver disease in US adults (2017-2020).**
Fouad Y., Kawaguchi T., Yilmaz Y.
Liver international : official journal of the International Association for the Study of the Liver, vol.44, no.11, pp.3112-3113, 2024 (SCI-Expanded)
- XXXVI. **Metabolic dysfunction associated fatty liver disease in healthy weight individuals**
Méndez-Sánchez N., Brouwer W. P., Lammert F., YILMAZ Y.
Hepatology International, vol.18, no. Suppl 2, pp.884-896, 2024 (SCI-Expanded)
- XXXVII. **Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis**
YILMAZ Y.
Alimentary Pharmacology and Therapeutics, vol.60, no.7, pp.974-975, 2024 (SCI-Expanded)
- XXXVIII. **Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study**
Keskin M., Arsoy H. A., Kara O., SARANDÖL E., Koca N., YILMAZ Y.
Journal of Clinical Medicine, vol.13, no.19, 2024 (SCI-Expanded)
- XXXIX. **Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma**
Adali G., Aykut H., Bilgic N. M., YILMAZ Y.
Heliyon, vol.10, no.18, 2024 (SCI-Expanded)
- XL. **Diagnostic accuracy of non-invasive tests to screen for at-risk MASH—An individual participant data meta-analysis**
Mózes F. E., Lee J. A., Vali Y., Selvaraj E. A., Jayaswal A. N. A., Boursier J., de Lédinghen V., Lupşor-Platon M., YILMAZ Y., Chan W., et al.
Liver International, vol.44, no.8, pp.1872-1885, 2024 (SCI-Expanded)
- XLI. **A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.**
Zhang H., Targher G., Byrne C. D., Kim S. U., Wong V. W., Valenti L., Glickman M., Ponce J., Mantzoros C. S., Crespo J., et al.
Hepatology International, vol.18, no.4, pp.1178-1201, 2024 (SCI-Expanded)
- XLII. **Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study**
Ergenc I., Kara E., Yilmaz M. E., DEMİRTAŞ C. Ö., Keklikkiran Ç., Das T., BÜYÜK Y., ÇELİKEL Ç., Asliyuksek H., YILMAZ Y.
HELIYON, vol.10, no.14, 2024 (SCI-Expanded)
- XLIII. **The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease**
Younossi Z. M., AlQahtani S. A., Funuyet-Salas J., Romero-Gómez M., YILMAZ Y., Keklikkiran Ç., Alswat K., Yu M., Liu C., Fan J., et al.
JHEP REPORTS, vol.6, no.7, 2024 (SCI-Expanded)
- XLIV. **Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt**
Alqahtani S. A., YILMAZ Y., El-Kassas M., Alswat K., Sanai F., AlZahrani M., Abaalkhail F., AlShaikh M., Al-Hamoudi W. K., Nader F., et al.
Journal of Viral Hepatitis, vol.31, no.6, pp.300-308, 2024 (SCI-Expanded)
- XLV. **Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa**
Younossi Z. M., Golabi P., Paik J., Owraghi S., YILMAZ Y., El-Kassas M., Alswat K., Alqahtani S. A.
Liver International, vol.44, no.4, pp.1061-1070, 2024 (SCI-Expanded)
- XLVI. **Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results**

- from a single-center biopsy study**
Kaya E., YILMAZ Y.
Chinese Medical Journal, vol.137, no.5, pp.616-618, 2024 (SCI-Expanded)
- XLVII. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease**
Younossi Z. M., Alqahtani S. A., Alswat K., YILMAZ Y., Keklikkiran Ç., Funuyet-Salas J., Romero-Gómez M., Fan J., Zheng M., El-Kassas M., et al.
JOURNAL OF HEPATOLOGY, vol.80, no.3, 2024 (SCI-Expanded)
- XLVIII. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.**
Hirschfield G. M., Bowlus C. L., Mayo M. J., Kremer A. E., Vierling J. M., Kowdley K. V., Levy C., Villamil A., Ladrón De Guevara Cetina A. L., Janczewska E., et al.
The New England journal of medicine, vol.390, no.9, pp.783-794, 2024 (SCI-Expanded)
- XLIX. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.**
Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Duseja A., Grønbæk H., Ismail M. H., Jepsen P., Kanwal F., et al.
Hepatology communications, vol.8, no.2, 2024 (SCI-Expanded)
- L. A global action agenda for turning the tide on fatty liver disease**
Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., Alazawi W., Alkhouri N., Alqahtani S. A., Anstee Q. M., et al.
Hepatology, vol.79, no.2, pp.502-523, 2024 (SCI-Expanded)
- LI. Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review**
Kaya E., YILMAZ Y.
Turkish Journal of Gastroenterology, vol.35, no.2, pp.76-82, 2024 (SCI-Expanded)
- LII. Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time**
El-Kassas M., Alswat K., Tharwat M., Labidi A., Medhat M. A., Sanai F. M., Benazzouz M., Tumi A., YILMAZ Y., Elzouki A.
Journal of Hepatology, vol.80, no.2, 2024 (SCI-Expanded)
- LIII. Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders**
DEMİRTAŞ C. Ö., YILMAZ Y.
Journal of Clinical and Translational Hepatology, vol.12, no.10, pp.857-864, 2024 (SCI-Expanded)
- LIV. Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes**
Çebi M., Yılmaz Y.
Frontiers in Immunology, vol.15, 2024 (SCI-Expanded)
- LV. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease**
Feng G., Valenti L., Wong V. W., Fouad Y. M., YILMAZ Y., Kim W., Sebastiani G., Younossi Z. M., Hernandez-Gea V., Zheng M.
Nature Reviews Gastroenterology and Hepatology, vol.21, no.1, pp.46-56, 2024 (SCI-Expanded)
- LVI. Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction**
Kaya E., YILMAZ Y., Alkhouri N.
Expert Opinion on Investigational Drugs, vol.33, no.12, pp.1167-1176, 2024 (SCI-Expanded)
- LVII. Can Frequent Toothbrushing Reduce the Risk of Cirrhosis among Patients with Non-alcoholic Fatty Liver Disease? Hints from a Registry-based Study**
Keklikkiran Ç., Stepanova M., Younossi Z., Yilmaz Y.
DIGESTIVE DISEASES, vol.41, no.6, pp.932-937, 2023 (SCI-Expanded)
- LVIII. Brushing your teeth may be good for your liver: Linking oral health to non-alcoholic fatty liver disease**

- YILMAZ Y.
Annals of Hepatology, vol.28, no.6, 2023 (SCI-Expanded)
- LIX. **A global research priority agenda to advance public health responses to fatty liver disease.**
 Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., Alazawi W., Alkhouri N., Alqahtani S. A., Arrese M., et al.
Journal of hepatology, 2023 (SCI-Expanded)
- LX. **A multi-society Delphi consensus statement on new fatty liver disease nomenclature.**
 Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M., Sanyal A. J., Kanwal F., Romero D., Abdelmalek M. F., Anstee Q. M., Arab J. P., et al.
Journal of hepatology, 2023 (SCI-Expanded)
- LXI. **A multi-society Delphi consensus statement on new fatty liver disease nomenclature.**
 Rinella M. E., Lazarus J. V., Ratziu V., Francque S. M., Sanyal A. J., Kanwal F., Romero D., Abdelmalek M. F., Anstee Q. M., Arab J. P., et al.
Annals of hepatology, pp.101133, 2023 (SCI-Expanded)
- LXII. **An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease**
 Sun D., Targher G., Byrne C. D., Wheeler D. C., Wong V. W., Fan J., Tilg H., Yuan W., Wanner C., Gao X., et al.
HEPATOBILIARY SURGERY AND NUTRITION, vol.12, no.3, 2023 (SCI-Expanded)
- LXIII. **Asia-Pacific association for study of liver guidelines on management of ascites in liver disease.**
 Singh V., De A., Mehtani R., Angeli P., Maiwall R., Satapathy S., Singal A. K., Saraya A., Sharma B. C., Eapen C. E., et al.
Hepatology international, 2023 (SCI-Expanded)
- LXIV. **An international multidisciplinary consensus statement on MAFLD and the risk of CVD.**
 Zhou X., Targher G., Byrne C. D., Somers V., Kim S. U., Chahal C. A. A., Wong V. W., Cai J., Shapiro M. D., Eslam M., et al.
Hepatology international, pp.1-19, 2023 (SCI-Expanded)
- LXV. **Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study.**
 Anstee Q. M., Lucas K. J., Francque S., Abdelmalek M. F., Sanyal A. J., Ratziu V., Gadano A. C., Rinella M., Charlton M., Loomba R., et al.
Hepatology (Baltimore, Md.), 2023 (SCI-Expanded)
- LXVI. **Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease**
 Pan Q., Fan J., Yilmaz Y.
CLINICS IN LIVER DISEASE, vol.27, no.00, pp.317-332, 2023 (SCI-Expanded)
- LXVII. **Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)**
 Younossi Z. M., Yu M., Yilmaz Y., Alswat K. A., Buti M., Fernandez M. I. C., Papatheodoridis G., Hamid S. S., El-Kassas M., Chan W. K., et al.
JOURNAL OF VIRAL HEPATITIS, vol.30, no.4, pp.335-344, 2023 (SCI-Expanded)
- LXVIII. **Geographical similarity and differences in the burden and genetic predisposition of NAFLD**
 Yip T. C., Vilar-Gomez E., Petta S., Yilmaz Y., Wong G. L., Adams L. A., De Lédinghen V., Sookoian S., Wong V. W.
HEPATOLOGY, vol.77, no.4, pp.1404-1427, 2023 (SCI-Expanded)
- LXIX. **Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.**
 Pennisi G., Enea M., Falco V., Aithal G. P., Palaniyappan N., Yilmaz Y., Boursier J., Cassinotto C., De Lédinghen V., Chan W. K., et al.
Hepatology (Baltimore, Md.), 2023 (SCI-Expanded)
- LXX. **Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.**
 Sanyal A. J., Fouquerier J., Younossi Z. M., Harrison S. A., Newsome P. N., Chan W., Yilmaz Y., De Ledinghen V., Costentini C., Zheng M., et al.
Journal of hepatology, vol.78, no.2, pp.247-259, 2023 (SCI-Expanded)
- LXXI. **Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis**

- risk diagnosis: an international registry study.**
Zhang H., Rios R. S., Boursier J., Anty R., Chan W., George J., Yilmaz Y., Wong V. W., Fan J., Dufour J., et al.
Chinese medical journal, vol.136, pp.341-350, 2023 (SCI-Expanded)
- LXXII. **Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study**
Yilmaz Y., Toraman A. E., Alp C., Doğan Z., Keklikkiran Ç., Stepanova M., Younossi Z.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.57, no.2, pp.215-223, 2023 (SCI-Expanded)
- LXXIII. **Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice**
Lazarus J. V., Castera L., Mark H. E., Allen A. M., Adams L. A., Anstee Q. M., Arrese M., Alqahtani S. A., Bugianesi E., Colombo M., et al.
JHEP REPORTS, vol.5, no.1, pp.100596-100601, 2023 (SCI-Expanded)
- LXXIV. **Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply.**
Yilmaz Y., Younossi Z.
Alimentary pharmacology & therapeutics, vol.57, no.2, pp.259-260, 2023 (SCI-Expanded)
- LXXV. **Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease**
Kaya E., Yilmaz Y.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, vol.13, pp.1-13, 2022 (SCI-Expanded)
- LXXVI. **The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease.**
Ozlu T., Yilmaz Y., Gunes F. E.
Minerva gastroenterology, vol.68, pp.426-433, 2022 (SCI-Expanded)
- LXXVII. **Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry**
Younossi Z. M., Yu M., El-Kassas M., Esmat G., Fernandez M. I. C., Buti M., Papatheodoridis G., Yilmaz Y., Isakov V., Duseja A., et al.
JOURNAL OF VIRAL HEPATITIS, vol.29, no.11, pp.1015-1025, 2022 (SCI-Expanded)
- LXXVIII. **DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**
Younossi Z. M., Stepanova M., Fernandez M. I. C., Yilmaz Y., Yu M., El Kassas M., Esmat G., Isakov V. A., Wong V. W., Eguchi Y., et al.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- LXXIX. **Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.**
Younossi Z. M., Yilmaz Y., Yu M., Wai-Sun Wong V., Fernandez M. C., Isakov V. A., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.20, pp.2296-2312, 2022 (SCI-Expanded)
- LXXX. **The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry**
Younossi Z. M., Yilmaz Y., El-Kassas M., Duseja A., Hamid S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B., et al.
HEPATOLOGY COMMUNICATIONS, vol.6, no.10, pp.2860-2866, 2022 (SCI-Expanded)
- LXXXI. **HEPATOCYTE APOPTOSIS FRAGMENT PRODUCT CYTOKERATIN-18 M30 AND NON-ALCOHOLIC STEATOHEPATITIS RISK PREDICTION: AN INTERNATIONAL REGISTRY STUDY**
Zhang H., Rios R. S., Boursier J., Anty R., Chan W., George J., Yilmaz Y., Wong V. W., Sookoian S., Fan J., et al.
GUT, vol.71, 2022 (SCI-Expanded)
- LXXXII. **Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging**

- Ratziu V., Yilmaz Y., Lazas D., Friedman S., Lackner C., Behling C., Cummings O., Chen L., Petitjean M., Gilgun-Sherki Y., et al.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LXXXIII. **Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part**
Ratziu V., YILMAZ Y., Lazas D., Friedman S., Hayardeny L., Kadosh S., Gorfine T., Sanyal A.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LXXXIV. **Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease**
Younossi Z., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Ong J., et al.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LXXXV. **Lean non-alcoholic fatty liver disease patients from the global NASH registry**
Younossi Z., YILMAZ Y., Yu M., Wong V. W., Castellanos-Fernandez M., Isakov V., Duseja A. K., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- LXXXVI. **A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.**
Younossi Z. M., Ong J. P., Takahashi H., Yilmaz Y., Eguchi Y., El Kassas M., Buti M., Diago M., Zheng M., Fan J., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.20, 2022 (SCI-Expanded)
- LXXXVII. **Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.**
Mózes F. E., Lee J. A., Selvaraj E. A., Jayaswal A. N. A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R. E., Bugianesi E., et al.
Gut, vol.71, pp.1006-1019, 2022 (SCI-Expanded)
- LXXXVIII. **Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus**
Yetginoglu O., Atas D. B., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Asicioglu E.
Lupus, vol.31, no.6, pp.723-729, 2022 (SCI-Expanded)
- LXXXIX. **Global multi-stakeholder endorsement of the MAFLD definition**
Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., Sarin S. K., Fabrellas N., Zelber-Sagi S., Fan J., et al.
The Lancet Gastroenterology and Hepatology, vol.7, no.5, pp.388-390, 2022 (SCI-Expanded)
- XC. **Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver**
Kaya E., Yilmaz Y.
Journal of Clinical and Translational Hepatology, vol.10, no.2, pp.329-338, 2022 (SCI-Expanded)
- XCI. **The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?**
Lazarus J. V., Mark H. E., Villota-Rivas M., Palayew A., Carrieri P., Colombo M., Ekstedt M., Esmat G., George J., Marchesini G., et al.
Journal of hepatology, vol.76, pp.771-780, 2022 (SCI-Expanded)
- XCII. **Advancing the global public health agenda for NAFLD: a consensus statement**
Lazarus J., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M. A., et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, vol.19, pp.60-78, 2022 (SCI-Expanded)
- XCIII. **Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.**
Eren F., Kaya E., Yilmaz Y.
European journal of gastroenterology & hepatology, vol.34, pp.98-103, 2022 (SCI-Expanded)
- XCIV. **Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids.**

- Guveli H., Kenger E. B., Ozlu T., Kaya E., Yilmaz Y.
 European journal of gastroenterology & hepatology, vol.33, 2021 (SCI-Expanded)
- XCV. **FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY**
 Younossi Z. M., YILMAZ Y., Wong V. W., Fernandez M. I. C., Bugianesi E., Burra P., Yu M., Chan W. K., Isakov V. A., Duseja A. K., et al.
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XCVI. **acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.**
 Wu X., Zheng K. I., Boursier J., Chan W., Yilmaz Y., Romero-Gómez M., El Kassas M., Targher G., Byrne C. D., Huang Z., et al.
EClinicalMedicine, vol.41, pp.101145, 2021 (SCI-Expanded)
- XCVII. **A NOVEL STUDY DESIGN WITH ARAMCHOL EXPLORING THE KINETICS AND INTER-RELATIONS OF HISTOLOGICAL OUTCOME MEASURES AND NON-INVASIVE TESTS ASSOCIATED WITH NASH AND FIBROSIS FOR VARIABLE TREATMENT DURATIONS**
 Ratiu V., YILMAZ Y., Lazas D., De Guevara L. L., Kadosh S., Gorfine T., Sanyal A. J.
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XCVIII. **COVID-19 PANDEMIC AND CHRONIC LIVER DISEASE (CLD)**
 Younossi Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W. K., Singal A. K., Lam B. P., et al.
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XCIX. **Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease**
 KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.8, pp.661-666, 2021 (SCI-Expanded)
- C. **Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis**
 Mozes F., Lee J., Selvaraj E., Jayaswal A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R., Bugianesi E., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- CI. **Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**
 Younossi Z., Harrison S., Newsome P. N., Chan W., YILMAZ Y., de Ledinghen V., Costentin C., Zheng M., Wong V. W., Elkhashab M., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- CII. **The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**
 Younossi Z., YILMAZ Y., El-Kassas M., Duseja A. K., Hamid S. S., Esmat G., Mendez-Sanchez N., Chan W., Singal A., Lam B., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- CIII. **Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.**
 Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Grønbæk H., Ismail M., Jepsen P., Kanwal F., Kramer J., et al.
Hepatology (Baltimore, Md.), vol.74, pp.474-482, 2021 (SCI-Expanded)
- CIV. **Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?**
 Demirtas C. O., Yilmaz Y.
Alimentary pharmacology & therapeutics, vol.53, pp.1228-1229, 2021 (SCI-Expanded)
- CV. **Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study**
 Demirtas C. O., Keklikkiran Ç., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., Odabasi Z., Korten V., Yilmaz Y.

- INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021 (SCI-Expanded)
- CVI. **Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic**
AVCU A., Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.5, pp.466-472, 2021 (SCI-Expanded)
- CVII. **FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS**
YETGİNOĞLU Ö., Atas D. B., VELİOĞLU A., ARIKAN İ. H., YILMAZ Y., ALİBAZ ÖNER F., DİRESKENELİ R. H., TUĞLULAR Z. S., AŞICIÖĞLU E.
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, pp.172, 2021 (SCI-Expanded)
- CVIII. **A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.**
Yilmaz Y., Byrne C., Musso G.
Expert review of gastroenterology & hepatology, vol.15, pp.345-352, 2021 (SCI-Expanded)
- CIX. **Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.**
Demirtas C. Ö., Keklikkiran Ç., Mehdiyev S., Ergenç İ., Özgen Alahdab Y., Gündüz F., Yılmaz Y., Atuğ Ö., Özdoğan O. C.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.32, pp.113-115, 2021 (SCI-Expanded)
- CX. **The case for simplifying and using absolute targets for viral hepatitis elimination goals.**
Razavi H., Blach S., Razavi-Shearer D., Polaris O.
Journal of viral hepatitis, vol.28, pp.12-19, 2021 (SCI-Expanded)
- CXI. **The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease**
Eslam M., Sarin S., Wong V., Fan J., Kawaguchi T., Ahn S., Zheng M., Shiha G., Yilmaz Y., Gani R., et al.
HEPATOLOGY INTERNATIONAL, vol.14, no.6, pp.889-919, 2020 (SCI-Expanded)
- CXII. **Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening.**
Yilmaz Y., Kaya E., Eren F.
Alimentary pharmacology & therapeutics, vol.52, pp.1759-1760, 2020 (SCI-Expanded)
- CXIII. **Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study.**
Gündüz F., Kani H., Chang S., Akdeniz E., Eren F., Yilmaz Y., Alahdab Y.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.31, pp.676-680, 2020 (SCI-Expanded)
- CXIV. **Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.**
Saldırın T., Mutluay F., Yağcı İ., Yilmaz Y.
Annales d'endocrinologie, vol.81, pp.493-499, 2020 (SCI-Expanded)
- CXV. **Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.**
Hamurcu V., Kaya E., Alphan E., Yilmaz Y.
European journal of gastroenterology & hepatology, vol.32, pp.1352-1357, 2020 (SCI-Expanded)
- CXVI. **Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.**
Sun D., Ye F., Kani H., Yang J., Zheng K., Zhang H., Targher G., Byrne C., Chen Y., Yuan W., et al.
Diabetes & metabolism, vol.46, pp.288-295, 2020 (SCI-Expanded)
- CXVII. **A new definition for metabolic associated fatty liver disease: an international expert consensus statement.**
Eslam M., Newsome P., Anstee Q., Targher G., Gomez M., Zelber-Sagi S., Wong V., Dufour J., Schattenberg J., Arrese M., et al.

- Journal of hepatology, vol.73, pp.202-209, 2020 (SCI-Expanded)
- CXVIII. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.**
- Kaya E., Bakir A., Kani H., Demirtas C., Keklikiran Ç., Yilmaz Y.
Gut and liver, vol.14, pp.486-491, 2020 (SCI-Expanded)
- CXIX. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients**
- Demirtas C., Gunduz F., Kani H., Keklikiran Ç., Alahdab Y., Yilmaz Y., Duman D., Atug O., Giral A., Aslan R., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.32, no.7, pp.882-888, 2020 (SCI-Expanded)
- CXX. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.**
- Eslam M., Sanyal A., George J., International C.
Gastroenterology, vol.158, 2020 (SCI-Expanded)
- CXXI. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study**
- Jafarov F., Kaya E., Bakir A., Eren F., Yilmaz Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.32, pp.642-649, 2020 (SCI-Expanded)
- CXXII. The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.**
- Enc F., Ulasoglu C., Bakir A., Yilmaz Y.
European journal of gastroenterology & hepatology, vol.32, pp.597-600, 2020 (SCI-Expanded)
- CXXIII. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.**
- Newsome P., Sasso M., Deeks J., Paredes A., Boursier J., Chan W., Yilmaz Y., Czernichow S., Zheng M., Wong V., et al.
The lancet. Gastroenterology & hepatology, vol.5, pp.362-373, 2020 (SCI-Expanded)
- CXXIV. Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.**
- Yilmaz Y.
Alimentary pharmacology & therapeutics, vol.51, pp.669-670, 2020 (SCI-Expanded)
- CXXV. Letter: the perilous road to a functional cure for hepatitis B infection.**
- Yilmaz Y.
Alimentary pharmacology & therapeutics, vol.51, pp.577, 2020 (SCI-Expanded)
- CXXVI. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.**
- Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y.
Acta diabetologica, 2020 (SCI-Expanded)
- CXXVII. NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?**
- Yilmaz Y., Eren F.
ANGIOLOGY, vol.71, pp.83-84, 2020 (SCI-Expanded)
- CXXVIII. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.**
- Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikiran Ç., Yilmaz Y.
European journal of gastroenterology & hepatology, vol.32, pp.54-57, 2020 (SCI-Expanded)
- CXXIX. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.**
- Ulasoglu C., Enc F., Kaya E., Yilmaz Y.
Journal of gastrointestinal and liver diseases : JGLD, vol.28, pp.427-431, 2019 (SCI-Expanded)
- CXXX. Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"**
- Yilmaz Y., Eren F.
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, vol.29, no.6, pp.548, 2019 (SCI-Expanded)
- CXXXI. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients**

- with non-alcoholic steatohepatitis**
Hasturk B., Yilmaz Y., Eren F.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.18, pp.463-475, 2019 (SCI-Expanded)
- CXXXII. Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter**
Yilmaz Y., Eren F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.12, pp.1601-1602, 2019 (SCI-Expanded)
- CXXXIII. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.**
Tatar B., Köse S., Ergun N., Turken M., Onlen Y., Yilmaz Y., Akhan S.
Revista da Associacao Medica Brasileira (1992), vol.65, pp.1470-1475, 2019 (SCI-Expanded)
- CXXXIV. Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease**
Yilmaz Y., Eren F.
ATHEROSCLEROSIS, vol.290, pp.222-223, 2019 (SCI-Expanded)
- CXXXV. Non-alcoholic fatty liver disease: A growing public health problem in Turkey**
Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.10, pp.865-871, 2019 (SCI-Expanded)
- CXXXVI. Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents**
Kesen O., Kani H., Yanartaş Ö., Aykut U., Gök B., Gündüz F., Yilmaz Y., Özdoğan O. C., Özgen A.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.9, pp.801-806, 2019 (SCI-Expanded)
- CXXXVII. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease**
Younossi Z. M., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., El Kassas M., Castellanos-Fernandez M., George J., Jacobson I. M., et al.
Clinical Gastroenterology and Hepatology, vol.17, pp.1625, 2019 (SCI-Expanded)
- CXXXVIII. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis**
Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., Wai-Sun Wong V., Yilmaz Y., George J., Fan J., et al.
Hepatology, vol.69, pp.2672-2682, 2019 (SCI-Expanded)
- CXXXIX. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**
Dq S., Fang Zhoa Y., KANİ H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.
Journal Of Hepatology, vol.70, pp.787, 2019 (SCI-Expanded)
- CXL. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates**
Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., Eguchi Y., Wong V. W., Negro F., Yilmaz H. Y., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.17, no.4, pp.748-758, 2019 (SCI-Expanded)
- CXLI. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study**
DEMİR M., Deyneli O., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.3, pp.266-270, 2019 (SCI-Expanded)
- CXLII. The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients**
Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., Demirtas C. O., DEMİRTAŞ C. Ö., KANİ H. T.,

- YILMAZ Y.
Hepatology International, vol.13, pp.196, 2019 (SCI-Expanded)
- CXLIII. **Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.**
Yilmaz Y., Kani H. T., Demirtaş C., Kaya E., Sapmaz A., Qutranji L., Alkayyali T., Batun K., Batman M., Toy B., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.30, pp.892-898, 2019 (SCI-Expanded)
- CXLIV. **Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology**
YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.1, pp.43-46, 2019 (SCI-Expanded)
- CXLV. **THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS**
Önal O., Eren F., Yilmaz D., Göçmen T., Yilmaz Y.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, vol.6, pp.135, 2018 (SCI-Expanded)
- CXLVI. **Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Comsumption and Metabolic Syndrome on Mortality**
Younossi Z., Maria S., Ong J., Yilmaz Y., Duseja A., Eguchi Y., Elkassas M., Castel L., Fernandez V., George J., et al.
Hepatology, vol.68, pp.1, 2018 (SCI-Expanded)
- CXLVII. **Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH**
Yilmaz D., Eren F., Göçmen T., Yilmaz Y.
Journal Of Biotechnology, vol.280, pp.76, 2018 (SCI-Expanded)
- CXLVIII. **The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease**
Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., Turker T., YILMAZ Y., Uygun A.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.30, no.4, pp.411-417, 2018 (SCI-Expanded)
- CXLIX. **The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children**
Tutar E., Şahin Akkelle B., Kesici C. B., Yilmaz Y., Çelikel Ç., Ergelen R., Ertem Şahinoğlu D.
Journal Of Pediatric Gastroenterology And Nutrition, vol.66, 2018 (SCI-Expanded)
- CL. **Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma**
Yilmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.
Hepatology International, vol.12, 2018 (SCI-Expanded)
- CLI. **Recommendation for treatment of hepatitis C virus infection**
KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., AKYÜZ F., Bodur H., ÇAĞATAY A. A., Dincer D., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)
- CLII. **Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases**
YILMAZ Y., EREN F.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, no.5, pp.327-328, 2017 (SCI-Expanded)
- CLIII. **The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study**
Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., Yilmaz Y., Kurt O., Turker T., Vatansever S., et al.
European Journal of Gastroenterology and Hepatology, vol.29, pp.441-447, 2017 (SCI-Expanded)
- CLIV. **Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter**
Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.28, no.11, pp.1264-1267, 2016 (SCI-Expanded)
- CLV. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**

- ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., Altun E., TÜNEY D.
ABDOMINAL RADIOLOGY, vol.41, no.8, pp.1505-1510, 2016 (SCI-Expanded)
- CLVI. **The role of active brown adipose tissue in human metabolism**
Ozguven S., Ones T., Yilmaz Y., Turoglu H. T., Imeryuz N.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.43, no.2, pp.355-361, 2016 (SCI-Expanded)
- CLVII. **Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning**
Akyüz Ü., Yilmaz Y., Ince A. T., Kaya B., Pata C.
Gastroenterology Research and Practice, vol.2016, 2016 (SCI-Expanded)
- CLVIII. **Is NAFLD different in absence of metabolic syndrome?**
YILMAZ Y.
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE, pp.44-49, 2016 (SCI-Expanded)
- CLIX. **Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease**
Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., Yilmaz Y., Agirbasli M.
CARDIOVASCULAR THERAPEUTICS, vol.33, pp.294-299, 2015 (SCI-Expanded)
- CLX. **Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease**
Dincses E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.10, pp.1149-1153, 2015 (SCI-Expanded)
- CLXI. **Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease**
Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., Ozkanli S., Oltulu Y. M., Coskunpinar E., TUNCER İ.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.21, no.26, pp.8096-8102, 2015 (SCI-Expanded)
- CLXII. **Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease**
ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.6, pp.667-671, 2015 (SCI-Expanded)
- CLXIII. **Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels**
Akyuz U., Yesil A., YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.50, no.3, pp.341-346, 2015 (SCI-Expanded)
- CLXIV. **Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease**
Subasi C. F., Aykut U. E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.2, pp.137-141, 2015 (SCI-Expanded)
- CLXV. **Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians**
Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., Lucia A.
REJUVENATION RESEARCH, vol.17, no.6, pp.518-524, 2014 (SCI-Expanded)
- CLXVI. **No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects**
Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.6, pp.639-643, 2014 (SCI-Expanded)
- CLXVII. **Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.**
Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., Ergelen R., Yilmaz Y.
Atherosclerosis, vol.237, no.2, pp.490-3, 2014 (SCI-Expanded)

- CLXVIII. A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease**
 Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., ÇELİKEL Ç., YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.11, pp.1343-1348, 2014 (SCI-Expanded)
- CLXIX. ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY**
 Tasli B., YILMAZ Y.
RESPIROLOGY, vol.19, pp.189, 2014 (SCI-Expanded)
- CLXX. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease**
 YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.26, no.11, pp.1292-1295, 2014 (SCI-Expanded)
- CLXXI. A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators**
 ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., SENATES E., Takir M., Kostek O., YILMAZ Y., Enc F. Y., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.23, no.3, pp.311-319, 2014 (SCI-Expanded)
- CLXXII. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis**
 Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., Hultcrantz R., Hagstrom H., Yoon S. K., Charatcharoenwitthaya P., et al.
PLOS MEDICINE, vol.11, no.7, 2014 (SCI-Expanded)
- CLXXIII. Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply**
 Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.39, no.12, pp.1442, 2014 (SCI-Expanded)
- CLXXIV. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease**
 YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., TUNCER İ., Dolar E.
GUT AND LIVER, vol.8, no.3, pp.313-317, 2014 (SCI-Expanded)
- CLXXV. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy**
 YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., Imeryuz N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.5, pp.611-616, 2014 (SCI-Expanded)
- CLXXVI. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease**
 YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.
JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol.28, no.3, pp.328-331, 2014 (SCI-Expanded)
- CLXXVII. Obesity-Associated Nonalcoholic Fatty Liver Disease**
 YILMAZ Y., Younossi Z. M.
CLINICS IN LIVER DISEASE, vol.18, no.1, pp.19-32, 2014 (SCI-Expanded)
- CLXXVIII. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease**
 Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.38, no.9, pp.1038-1044, 2013 (SCI-Expanded)
- CLXXIX. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography**
 YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.25, no.11, pp.1330-1334, 2013 (SCI-Expanded)
- CLXXX. Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials**
 YILMAZ Y.

- CURRENT DRUG TARGETS, vol.14, no.11, pp.1357-1366, 2013 (SCI-Expanded)
- CLXXXI. Liver disease and malnutrition
Purnak T., YILMAZ Y.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, vol.27, no.4, pp.619-629, 2013 (SCI-Expanded)
- CLXXXII. Assessment of endothelial function in patients with nonalcoholic fatty liver disease
Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., Coskunpinar E., Kahraman O. T., MESCI B., Ulasoglu C., et al.
ENDOCRINE, vol.43, no.1, pp.100-107, 2013 (SCI-Expanded)
- CLXXXIII. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease
YILMAZ Y., Ozturk O., Alandab Y., Senates E., COLAK Y., Doganay H. L., Coskunpinar E., Oltulu Y. M., EREN F., ATUG Ö., et al.
DIGESTIVE AND LIVER DISEASE, vol.45, no.1, pp.58-62, 2013 (SCI-Expanded)
- CLXXXIV. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back
YILMAZ Y., COLAK Y., Kurt R., Senates E., EREN F.
TUMORI, vol.99, no.1, pp.10-16, 2013 (SCI-Expanded)
- CLXXXV. Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.37, no.2, pp.283, 2013 (SCI-Expanded)
- CLXXXVI. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis
YILMAZ Y., EREN F.
CLINICA CHIMICA ACTA, vol.414, pp.154-157, 2012 (SCI-Expanded)
- CLXXXVII. Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease
YILMAZ Y., EREN F., COLAK Y., Senates E., CELIKEL Ç., Imeryuz N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.12, pp.1488-1493, 2012 (SCI-Expanded)
- CLXXXVIII. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.9, pp.815-823, 2012 (SCI-Expanded)
- CLXXXIX. Research update for articles published in EJCI in 2010
Adlbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., Chang K., Chattipakorn N., Chattipakorn S. C., Chen Y., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.11, pp.1149-1164, 2012 (SCI-Expanded)
- CXC. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease
YILMAZ Y.
CLINICA CHIMICA ACTA, vol.413, pp.1190-1193, 2012 (SCI-Expanded)
- CXCI. Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.36, no.4, pp.345-352, 2012 (SCI-Expanded)
- CXCII. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease
Eren F., Kurt R., Ermis F., Atug Ö., Imeryuz N., Yilmaz Y.
Clinical Biochemistry, vol.45, pp.655-658, 2012 (SCI-Expanded)
- CXCIII. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis
YILMAZ Y., Yonal O., Deyneli O., CELIKEL Ç., Kalayci C., DUMAN D.
ACTA GASTRO-ENTEROLOGICA BELGICA, vol.75, no.2, pp.240-244, 2012 (SCI-Expanded)
- CXCIV. Nonalcoholic Fatty Liver Disease: A Nutritional Approach
COLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.

- METABOLIC SYNDROME AND RELATED DISORDERS, vol.10, no.3, pp.161-166, 2012 (SCI-Expanded)
- CXCV. **Review article: fructose in non-alcoholic fatty liver disease**
Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.35, pp.1135-1144, 2012 (SCI-Expanded)
- CXCVI. **Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease**
Kurt R., YILMAZ Y.
CLINICAL BIOCHEMISTRY, vol.45, no.6, pp.515, 2012 (SCI-Expanded)
- CXCVII. **Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis**
YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.47, no.4, pp.489-490, 2012 (SCI-Expanded)
- CXCVIII. **Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome**
YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., Dolar E., Kalayci C.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.42, no.4, pp.411-418, 2012 (SCI-Expanded)
- CXCIX. **Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology**
Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., Ulasoglu C., Aksaray S., Bozbeyoglu S. G., Kiziltas S., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.24, no.3, pp.255-261, 2012 (SCI-Expanded)
- CC. **Is M65 really better than M30 as a biomarker of hepatic fibrosis?**
YILMAZ Y., Kurt R.
HEPATOLOGY, vol.55, no.2, pp.654, 2012 (SCI-Expanded)
- CCI. **NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?**
YILMAZ Y.
SEMINARS IN LIVER DISEASE, vol.32, no.1, pp.14-21, 2012 (SCI-Expanded)
- CCII. **The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy**
Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., Abacioglu U., Imeryuz N.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.269, no.1, pp.275-282, 2012 (SCI-Expanded)
- CCIII. **Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**
COLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., Doganay L., MESCİ B., YILMAZ Y., Enc F. Y., et al.
DISEASE MARKERS, vol.33, no.2, pp.77-83, 2012 (SCI-Expanded)
- CCIV. **Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population**
Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., Yilmaz Y., Kalayci O., Kalayci C.
NEUROGASTROENTEROLOGY AND MOTILITY, vol.24, no.1, pp.27-30, 2012 (SCI-Expanded)
- CCV. **A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve nice olarak tespitine yönelik metodlara ki{dotless}sa bir baki{dotless}ş**
Ulukaya E., Acilan C., Ari F., Ikitimur E., Yilmaz Y.
Turkish Journal of Biochemistry, vol.36, pp.261-269, 2011 (SCI-Expanded)
- CCVI. **Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration**
YILMAZ Y., Kurt R., EREN F., Imeryuz N.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, vol.71, no.8, pp.631-636, 2011 (SCI-Expanded)
- CCVII. **Cytokeratins in hepatitis**

- YILMAZ Y.
CLINICA CHIMICA ACTA, vol.412, pp.2031-2036, 2011 (SCI-Expanded)
- CCVIII. **Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis**
YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., Tuncer I., Dolar E., Imeryuz N.
CLINICA CHIMICA ACTA, vol.412, pp.2296-2299, 2011 (SCI-Expanded)
- CCIX. **Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease**
Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., Sahin O., Zemheri E., Enc F. Y., Ulasoglu C., et al.
HEPATO-GASTROENTEROLOGY, vol.58, no.112, pp.2087-2090, 2011 (SCI-Expanded)
- CCX. **Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity**
Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.
Journal of Crohn's and Colitis, vol.5, no.5, pp.402-406, 2011 (SCI-Expanded)
- CCXI. **Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans**
Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., Turoglu H., Imeryuz N.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)
- CCXII. **Apoptosis: why and how does it occur in biology?**
ULUKAYA E., Acilan C., YILMAZ Y.
CELL BIOCHEMISTRY AND FUNCTION, vol.29, no.6, pp.468-480, 2011 (SCI-Expanded)
- CCXIII. **Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions**
YILMAZ Y., Kurt R.
HEPATITIS MONTHLY, vol.11, no.8, pp.669-670, 2011 (SCI-Expanded)
- CCXIV. **Serum galectin-3 levels in patients with nonalcoholic fatty liver disease**
YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., Bacha M., Imeryuz N.
CLINICAL BIOCHEMISTRY, vol.44, no.12, pp.955-958, 2011 (SCI-Expanded)
- CCXV. **Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.**
Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., Turoglu H. T., Imeryuz N.
Alimentary pharmacology & therapeutics, vol.34, no.3, pp.318-23, 2011 (SCI-Expanded)
- CCXVI. **Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease**
Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., Ozkara S., Aksaray S., Tuncer I., Ovunc A. O. K.
METABOLIC SYNDROME AND RELATED DISORDERS, vol.9, no.4, pp.287-290, 2011 (SCI-Expanded)
- CCXVII. **Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats**
YILMAZ Y., Kurt R., EREN F.
OBESITY SURGERY, vol.21, no.8, pp.1316-1317, 2011 (SCI-Expanded)
- CCXVIII. **Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?**
YILMAZ Y., Yonal O., Kurt R.
HEPATITIS MONTHLY, vol.11, no.7, pp.557, 2011 (SCI-Expanded)
- CCXIX. **Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"**
Yilmaz Y., Eren F.
Metabolism: Clinical and Experimental, vol.60, 2011 (SCI-Expanded)
- CCXX. **Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease**
YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., Polat N., EREN F., Imeryuz N., Oflaz H.
ATHEROSCLEROSIS, vol.217, no.1, pp.125-129, 2011 (SCI-Expanded)
- CCXXI. **Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease**
Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., et al.

- METABOLISM-CLINICAL AND EXPERIMENTAL, vol.60, no.4, pp.544-549, 2011 (SCI-Expanded)
- CCXXII. **Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori**
Bekar O., YILMAZ Y., Gulten M.
JOURNAL OF MEDICINAL FOOD, vol.14, no.4, pp.344-347, 2011 (SCI-Expanded)
- CCXXIII. **Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis**
Yilmaz Y., Ulukaya E.
CURRENT MEDICINAL CHEMISTRY, vol.18, no.5, pp.725-732, 2011 (SCI-Expanded)
- CCXXIV. **Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease**
YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.
HEPATITIS MONTHLY, vol.11, no.2, pp.103-107, 2011 (SCI-Expanded)
- CCXXV. **Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.**
Ari E., Yilmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., Koçak H., Macunluoglu B., Atakan A., Kahveci A., et al.
American journal of nephrology, vol.33, no.3, pp.269-76, 2011 (SCI-Expanded)
- CCXXVI. **Serum levels of omentin, chemerin and adiponectin in patients with biopsy-proven nonalcoholic fatty liver disease**
Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., Celikel C. A., Imeryuz N., Kalayci C., Avsar E.
Scandinavian Journal of Gastroenterology, vol.46, pp.91-97, 2011 (SCI-Expanded)
- CCXXVII. **Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease**
Yilmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., Ozturk O., Avsar E.
Disease Markers, vol.31, pp.205-210, 2011 (SCI-Expanded)
- CCXXVIII. **Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease**
Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel C. A., Ulukaya E., Imeryuz N., Kalayci C., Avsar E.
Archives of Medical Research, vol.42, pp.38-43, 2011 (SCI-Expanded)
- CCXXIX. **Serum zinc- α 2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease**
Yilmaz Y., Yonal O., Eren F., Kurt R., Celikel C. A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.
Clinical Chemistry and Laboratory Medicine, vol.49, pp.93-97, 2011 (SCI-Expanded)
- CCXXX. **Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B**
EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., Ozdogan O., Avsar E.
CLINICA CHIMICA ACTA, vol.411, pp.2029-2032, 2010 (SCI-Expanded)
- CCXXXI. **Liver Enzymes and Cardiovascular Outcomes a New Research Agenda**
YILMAZ Y., Kuri R., Kalayci C.
HEPATOLOGY, vol.52, no.6, pp.2242, 2010 (SCI-Expanded)
- CCXXXII. **Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease**
Yilmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., Ari F., Çelikel Ç., Korkmaz S., Ulukaya E., et al.
Scandinavian Journal of Clinical and Laboratory Investigation, vol.70, pp.541-546, 2010 (SCI-Expanded)
- CCXXXIII. **Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis**
YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., KORKMAZ Ş., ULUKAYA E., Ozdogan O., Imeryuz N., et al.
ANNALS OF CLINICAL BIOCHEMISTRY, vol.47, pp.549-553, 2010 (SCI-Expanded)
- CCXXXIV. **Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease**
YILMAZ Y., Eren F., Yonal O., Kurt R., Aktas B., ÇELİKEL Ç., Ozdogan O., Imeryuz N., Kalayci C., Avsar E.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol.40, no.10, pp.887-892, 2010 (SCI-Expanded)
- CCXXXV. **Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments**

- YILMAZ Y., Kurt R., Kalayci C.
BIOMARKERS IN MEDICINE, vol.4, no.5, pp.743-745, 2010 (SCI-Expanded)
- CCXXXVI. **Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis**
YILMAZ Y., Alahdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., Ozdogan O., DUMAN D., Imeryuz N., Avsar E., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.59, no.9, pp.1327-1330, 2010 (SCI-Expanded)
- CCXXXVII. **Microalbuminuria and nonalcoholic fatty liver disease**
Yilmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.
Metabolism: Clinical and Experimental, vol.59, 2010 (SCI-Expanded)
- CXXXVIII. **Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease**
YILMAZ Y., Yonai O., Kurt R., Avsar E.
HEPATOLOGY, vol.52, no.1, pp.391, 2010 (SCI-Expanded)
- CCXXXIX. **Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency**
Kurt R., YILMAZ Y., Ermis F., Besik S. K., Polat N., Elitok A., Oflaz H., Karan M. A.
ARCHIVES OF MEDICAL RESEARCH, vol.41, no.5, pp.369-372, 2010 (SCI-Expanded)
- CCXL. **The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts**
Yilmaz Y.
JOURNAL OF GASTROENTEROLOGY, vol.45, no.7, pp.782-783, 2010 (SCI-Expanded)
- CCXLI. **Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis**
YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., Oflaz H., Ozdogan O., Imeryuz N., Kalayci C., et al.
ATHEROSCLEROSIS, vol.211, no.1, pp.182-186, 2010 (SCI-Expanded)
- CCXLII. **Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future**
YILMAZ Y., ULUKAYA E.
HEPATOLOGY, vol.51, no.5, pp.1866, 2010 (SCI-Expanded)
- CCXLIII. **The Impact of Prophylactic Percutaneus Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy**
Yonal O., Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., Kalayci C., Imeryuz N.
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXLIV. **C-KIT Gene Polymorphism in Achalasia**
Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., Imeryuz N., Giral A., Avsar E., Kalayci C.
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXLV. **Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis**
YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel C. A., Duman D., Ozdogan O., Imeryuz N., Avsar E., et al.
GASTROENTEROLOGY, vol.138, no.5, 2010 (SCI-Expanded)
- CCXLVI. **Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis**
Olmez O. F., Gurel S., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.22, no.4, pp.461-465, 2010 (SCI-Expanded)
- CCXLVII. **M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome**
Yilmaz Y., Kurt R.
Journal Of Clinical Endocrinology, vol.0, no.0, 2010 (SCI-Expanded)
- CCXLVIII. **Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients**
Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., YILMAZTEPE ORAL A., Guclu M., ERSOY C., Imamoglu S.
METABOLISM-CLINICAL AND EXPERIMENTAL, vol.59, no.1, pp.64-69, 2010 (SCI-Expanded)

- CCXLIX. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease**
Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.
Coronary Artery Disease, vol.20, pp.494-498, 2009 (SCI-Expanded)
- CCL. Metformin, hepatitis C, and insulin resistance: Sufficient evidence?**
Yilmaz Y., Yonal O., Imeryuz N.
Hepatology, vol.50, pp.2054-2055, 2009 (SCI-Expanded)
- CCLI. Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease**
Yilmaz Y.
Alimentary Pharmacology and Therapeutics, vol.30, pp.1103-1109, 2009 (SCI-Expanded)
- CCLII. Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?**
Yilmaz Y., Baran B., Seniz N. B., Dolar E.
Journal of Gastrointestinal and Liver Diseases, vol.18, pp.119-120, 2009 (SCI-Expanded)
- CCLIII. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients**
Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., Kocamaz G., Dilek K.
Medical Science Monitor, vol.15, 2009 (SCI-Expanded)
- CCLIV. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance**
Yilmaz Y., Ulukaya E., Atug Ö., Dolar E.
European Journal of Gastroenterology and Hepatology, vol.21, pp.1247-1251, 2009 (SCI-Expanded)
- CCLV. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.**
Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., Aydin A., Arikan H., Ozener C.
American journal of reproductive immunology (New York, N.Y.: 1989), vol.62, no.4, pp.238-42, 2009 (SCI-Expanded)
- CCLVI. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance**
Yilmaz Y., Alahdab Y., Özdogan O. C., Dolar E.
Internal Medicine Journal, vol.39, pp.709-710, 2009 (SCI-Expanded)
- CCLVII. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis**
YILMAZ Y., Kedrah A. E., Ozdogan O.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.15, no.35, pp.4387-4391, 2009 (SCI-Expanded)
- CCLVIII. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?**
YILMAZ Y., Dolar E.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.15, no.34, pp.4346-4347, 2009 (SCI-Expanded)
- CCLIX. "Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18**
Yilmaz Y.
HEPATOLOGY, vol.50, no.3, pp.990-991, 2009 (SCI-Expanded)
- CCLX. Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"**
YILMAZ Y., Dolar E., ULUKAYA E.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.49, no.3, pp.371, 2009 (SCI-Expanded)
- CCLXI. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond**
Yilmaz Y., Ulukaya E., Dolar E.
Hepatology, vol.49, pp.1056-1057, 2009 (SCI-Expanded)
- CCLXII. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels**

- Yilmaz Y., Ulukaya E., Dolar E.
Hepatology, vol.49, pp.697, 2009 (SCI-Expanded)
- CCLXIII. **Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C**
Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Yerci O., Oral A. Y., Gul C. B., Gurel S., et al.
Medical Science Monitor, vol.15, 2009 (SCI-Expanded)
- CCLXIV. **Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C**
ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.18, no.2, pp.256, 2009 (SCI-Expanded)
- CCLXV. **Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease**
YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., YILMAZTEPE ORAL A., Aker S., Dolar E.
CLINICAL BIOCHEMISTRY, vol.42, no.9, pp.802-807, 2009 (SCI-Expanded)
- CCLXVI. **Coronary artery anomalies in patients with syndrome X**
Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Ayndinlar A.
Anadolu Kardiyoloji Dergisi, vol.9, pp.69, 2009 (SCI-Expanded)
- CCLXVII. **Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis**
Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., Ozdogan O., ÇELİKEL Ç., Imeryuz N., Tozun N.
ARCHIVES OF MEDICAL RESEARCH, vol.40, no.4, pp.294-298, 2009 (SCI-Expanded)
- CCLXVIII. **Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity**
Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., Nak S., Erdinc S., Gulten M.
Internal Medicine Journal, vol.39, pp.243-248, 2009 (SCI-Expanded)
- CCLXIX. **Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease**
YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., Kalayci C.
MEDICAL SCIENCE MONITOR, vol.15, no.4, 2009 (SCI-Expanded)
- CCLXX. **Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue**
YILMAZ Y., Ozdogan O.
HEPATOLOGY, vol.49, no.2, pp.698, 2009 (SCI-Expanded)
- CCLXXI. **Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report**
Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.
Human and Experimental Toxicology, vol.28, pp.63-65, 2009 (SCI-Expanded)
- CCLXXII. **Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid**
Fazlioğlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., Baran I., Aydinlar A.
Atherosclerosis, vol.202, pp.200-204, 2009 (SCI-Expanded)
- CCLXXIII. **Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry**
ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., Dolar E.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.44, no.12, pp.1471-1476, 2009 (SCI-Expanded)
- CCLXXIV. **Predictive value of the modified early warning score in a turkish emergency department**
Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.
European Journal of Emergency Medicine, vol.15, pp.338-340, 2008 (SCI-Expanded)
- CCLXXV. **Concomitant colitis in a patient with Behcet's disease**
Yilmaz Y., Dolar E.
Journal of Gastrointestinal and Liver Diseases, vol.17, no.4, pp.481-483, 2008 (SCI-Expanded)
- CCLXXVI. **A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments**
Yilmaz Y., Ulukaya E., Dolar E.
Obesity Surgery, vol.18, pp.1507-1508, 2008 (SCI-Expanded)

- CCLXXVII. **Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease**
Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., Dilek K.
Clinical Biochemistry, vol.41, pp.1055-1058, 2008 (SCI-Expanded)
- CCLXXVIII. **The Pro12Ala polymorphism of peroxisome proliferator-activated receptor- γ 2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease**
Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., Zorzetto M., Campo I., Lanati N., Emanuele E.
Clinical Biochemistry, vol.41, pp.981-985, 2008 (SCI-Expanded)
- CCLXXIX. **Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease**
Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.
Acta Cardiologica, vol.63, no.4, pp.467-471, 2008 (SCI-Expanded)
- CCLXXX. **Helicobacter pylori: A role in schizophrenia?**
Yilmaz Y., Gul C. B., Arabul M., Eren M. A.
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCLXXXI. **Apical ballooning syndrome: A metabolic form of cardiomyopathy?**
Yilmaz Y.
Medical Science Monitor, vol.14, 2008 (SCI-Expanded)
- CCLXXXII. **Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?**
Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., Yilmaz Y., Yurtkuran M.
Clinical Biochemistry, vol.41, pp.544-547, 2008 (SCI-Expanded)
- CCLXXXIII. **Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia**
Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., Dolar E.
Blood Coagulation and Fibrinolysis, vol.19, pp.243-246, 2008 (SCI-Expanded)
- CCLXXXIV. **The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease**
Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., Vignali L., Boiocchi C., Sbarsi I., Cuccia M.
Archives of Medical Research, vol.39, pp.320-325, 2008 (SCI-Expanded)
- CCLXXXV. **Psychopathology in the context of obesity: The adiponectin hypothesis**
Yilmaz Y.
Medical Hypotheses, vol.70, pp.902-903, 2008 (SCI-Expanded)
- CCLXXXVI. **Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study**
Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., Gullulu M.
Nephron - Clinical Practice, vol.108, 2008 (SCI-Expanded)
- CLXXXVII. **The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease**
Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.
Clinica Chimica Acta, vol.387, pp.109-112, 2008 (SCI-Expanded)
- CCLXXXVIII. **Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients**
Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., Sarandol E., Gurel S., Nak S. G., Gulten M.
World Journal of Gastroenterology, vol.13, pp.6027-6030, 2007 (SCI-Expanded)
- CCLXXXIX. **Clinical significance of activity of ALT enzyme in patients with hepatitis C virus**
Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.
World Journal of Gastroenterology, vol.13, pp.5481-5485, 2007 (SCI-Expanded)
- CCXC. **Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis**
Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Aker S., Yilmaztepe A., Gurel S., Gulten M., et al.
World Journal of Gastroenterology, vol.13, pp.837-844, 2007 (SCI-Expanded)

Articles Published in Other Journals

- I. **Enhancing the Understanding of Liver Fibrosis in Type 2 Diabetes: Methodological Considerations and Future Directions**
El-Kassas M., Alnaamani K. M., Yilmaz Y., Alswat K. A.
Journal of Clinical and Experimental Hepatology, vol.15, no.5, 2025 (ESCI)
- II. **The relationship between bacterial changes and dietary intervention in non-alcoholic fatty liver disease**
Öğuz E., YILMAZ Y., Güneş F. E.
Clinical Nutrition ESPEN, vol.68, pp.267-273, 2025 (ESCI)
- III. **Association of diet quality scores with risk of metabolic-associated fatty liver disease in Iranian population: a nested case-control study**
Taheri E., Yilmaz Y., Ghorat F., Moslem A., Zali M. R.
Journal of Diabetes and Metabolic Disorders, vol.24, no.1, 2025 (ESCI)
- IV. **Health-Promoting Effects of Black Tea: A Narrative Review of Clinical Trials.**
Yilmaz Y.
International journal of food science, vol.2025, pp.8560718, 2025 (ESCI)
- V. **Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma**
El-Kassas M., Othman H. A., Elbadry M., Alswat K., Yilmaz Y.
Journal of Clinical and Experimental Hepatology, vol.15, no.1, 2025 (ESCI)
- VI. **Pilots, Astronauts, and the Aerospace Microbiota: A Narrative Review of Occupational Impact.**
Minoretti P., Fontana J. M., Yilmaz Y.
Cureus, vol.16, no.10, 2024 (ESCI)
- VII. **Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients**
Ergenc I., Gozaydinoglu B., Keklikkiran C., YILMAZ Y.
Hepatology Forum, vol.5, no.3, pp.165-166, 2024 (Scopus)
- VIII. **Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action**
Kamani L., Rahat A., YILMAZ Y.
Hepatology Forum, vol.5, no.1, pp.1-2, 2024 (Scopus)
- IX. **Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study**
Sariyar N., KANİ H. T., ÇELİKEL Ç., YILMAZ Y.
Hepatology Forum, vol.5, no.1, pp.33-36, 2024 (Scopus)
- X. **Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with psoriasis: A cross-sectional study**
Aksoy A. N., Hancı B., Baskent M. F., Umutlu E. G., Kumas E. N., Emanet S. U., Yalcin M. O., Duzyol Z., Teker A. G., YILMAZ Y.
Hepatology Forum, vol.5, no.1, pp.29-32, 2024 (Scopus)
- XI. **Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study.**
Arslan A. Y., Celik S., Amin F., Caylak I., Kesaplı I., Kılıç I. B., Karakullukcu S., Ardic C., Yilmaz Y.
Hepatology forum, vol.5, no.2, pp.63-67, 2023 (ESCI)
- XII. **The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients**
ERGENÇ İ., Gozaydinoglu B., KEKLİKKİRAN C., YILMAZ Y.
Hepatology forum, vol.4, no.2, pp.69-73, 2023 (Peer-Reviewed Journal)
- XIII. **TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease**
Yilmaz Y., Zeybel M., Adalı G., Coşar A., Sertesen E., Sümer H., Bahcecioglu I. H., Şahin M., Kaya C. T., Ergün İ., et al.

- Hepatology forum, vol.4, no.1, pp.1-32, 2023 (Peer-Reviewed Journal)
- XIV. **The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease**
YILMAZ Y., Kaya E.
HEPATOLOGY FORUM, vol.4, no.2, 2023 (ESCI)
- XV. **Chronotype preference, sleep quality, and night-eating behaviors in patients with metabolic dysfunction-associated steatotic liver disease: Assessing the relationship with disease severity and fibrosis**
Sakalli Kani A., Ozercan A., Kani H. T., Eren F., Sayar K., Yilmaz Y.
Hepatology Forum, vol.4, no.3, pp.123-128, 2023 (Scopus)
- XVI. **Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease**
Eris T., Hassan M., Hikal Y., Sawah E., Daneshgar F., Teker A. G., Ozel F., Lüleci N. E., Kaya E., Yilmaz Y.
HEPATOLOGY FORUM, vol.4, no.1, pp.7-13, 2023 (ESCI)
- XVII. **Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan**
Yesil E. E., Yilmaz Y., Yesil A., Mese M., Kaya E., Bakir E. A.
HEPATOLOGY FORUM, vol.4, no.1, pp.14-18, 2023 (ESCI)
- XVIII. **The heated debate over NAFLD renaming: An ongoing saga**
YILMAZ Y.
Hepatology Forum, vol.4, no.3, pp.89-91, 2023 (Scopus)
- XIX. **Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease**
Kaya E., YILMAZ Y.
HEPATOLOGY FORUM, vol.3, no.2, pp.39-40, 2022 (ESCI)
- XX. **Prevention of hepatocellular carcinoma and surveillance of high risk patients**
Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.
Hepatology Forum, vol.3, pp.33-38, 2022 (ESCI)
- XXI. **Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial**
TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., TOSUN S., YAMAZHAN T., BOZKURT İ., GÜRBÜZ Y., et al.
Viral Hepatitis Journal, vol.27, no.3, pp.109-117, 2021 (ESCI)
- XXII. **The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study**
YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., ADALI G., ÇALIŞKAN KARTAL A., ŞEN İ., AHİSHALI E., et al.
Hepatology Forum, vol.2, no.2, pp.37-42, 2021 (ESCI)
- XXIII. **High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis**
ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., Çelikel Ç. A., YILMAZ Y.
Hepatology Forum, vol.1, no.2, pp.20-25, 2021 (ESCI)
- XXIV. **Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients**
Saldıran T. C., Mutluay F. K., Yagci İ., Yilmaz Y.
COMPARATIVE EXERCISE PHYSIOLOGY, vol.17, no.4, pp.393-401, 2021 (ESCI)
- XXV. **The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance**
DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., YILMAZ Y.
Hepatology Forum, vol.1, no.3, pp.101-108, 2020 (Peer-Reviewed Journal)
- XXVI. **Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?**
DEMİRTAŞ C. Ö., YILMAZ Y.

- Hepatology Forum, vol.1, no.3, pp.79-81, 2020 (Peer-Reviewed Journal)
- XXVII. **Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases**
DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., YAPALI S., VARDARELİ N. E., ÜNAL H. Ü., Çolakoğlu B., et al.
Hepatology Forum, vol.1, no.3, pp.88-96, 2020 (Peer-Reviewed Journal)
- XXVIII. **The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases**
Kaya E., Bakır A., Eren F., Yılmaz Y.
Hepatology Forum, vol.1, no.1, pp.8-13, 2020 (Scopus)
- XXIX. **The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients**
KENGER E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.
Hepatology Forum, vol.1, no.1, pp.14-19, 2020 (Peer-Reviewed Journal)
- XXX. **Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter**
Kani H. T., Deliktas I., YILMAZ Y.
MARMARA MEDICAL JOURNAL, vol.32, no.2, pp.68-70, 2019 (ESCI)
- XXXI. **Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?**
Yılmaz Y.
World Journal of Hepatology, vol.4, pp.332-334, 2012 (Scopus)
- XXXII. **A Glance at the methods for detection of apoptosis qualitatively and quantitatively**
Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.
A Glance at the methods for detection of apoptosis qualitatively and quantitatively, vol.36, pp.261-269, 2011 (Peer-Reviewed Journal)
- XXXIII. **Liver function tests: Association with cardiovascular outcomes**
Yılmaz Y.
World Journal of Hepatology, vol.2, pp.143-145, 2010 (Scopus)

Books

- I. **Non-invasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease**
KAYA E., YILMAZ Y.
in: Metabolic Steatotic Liver Disease Current Knowledge, Therapeutic Treatments, and Future Directions, HENRY LINDA, NGUYEN MINDIE, Editor, ELSEVIER, STANDFORD, pp.137-150, 2024
- II. **Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle**
Pan Q., Fan J., Yılmaz Y.
in: Clinics in Liver Disease: Update on Non-Alcoholic Steatohepatitis, Norman Gitlin, Zobair M. Younossi, Editor, Elsevier Science, Oxford/Amsterdam, Pennsylvania, pp.317-332, 2023
- III. **Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle**
Pan Q., Fan J., YILMAZ Y.
in: Update on Non-Alcoholic Steatohepatitis, Zobair M. Younossi, Editor, Elsevier, pp.317-332, 2023
- IV. **Covid-19 ve Karaciğer Yağlanması İlişkisi Nasıl Gelişmektedir?**
Demirtaş C. Ö., YILMAZ Y.
in: Türkiye Klinikleri Gastroenteroloji ve Covid-19, Ahmet Uygun, Editor, Türkiye Klinikleri, Ankara, pp.39-44, 2021
- V. **Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**
Kaya E., Yılmaz Y.
in: Obesity and Diabetes, Joel Faintuch, Salomão Faintuc, Editor, Springer-Verlag, Zürich, pp.1-987, 2020
- VI. **Alkol Dışı Yağlı Karaciğer Hastalığı**

- KEFELİ A., YILMAZ Y.
in: Hepatobiliyer Sistem ve Pankreas Hastalıkları, Kefeli, Ayşe, Editor, Akademisyen Yayınevi, Ankara, pp.193-209, 2020
- VII. **Non-alcoholic Fatty Liver Disease: A Global Public Health Issue**
KAYA E., YILMAZ Y.
in: Obesity and Diabetes, Faintuch, Joel, Faintuch, Salomão, Editor, Springer, pp.321-333, 2020
- VIII. **Epidemiology of Nonalcoholic Fatty Liver Disease in Turkey and in the World**
Kaya E., Yılmaz Y.
in: Türkiye Klinikleri Gastroenterhepatoloji-Özel Konular: Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019
- IX. **Türkiye'de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi**
Kaya E., YILMAZ Y.
in: Türkiye Klinikleri Gastroenterhepatoloji-Özel Konular Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editor, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, pp.1-7, 2019
- X. **Is NAFLD different in absence of metabolic syndrome?**
Yılmaz Y.
in: Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams, Simon D. Taylor-Robinson, Editor, Wiley-VCH Verlag Weinheim GmbH, London, pp.50-57, 2016
- XI. **Is NAFLD different in absence of metabolic syndrome?**
YILMAZ Y.
in: Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams, Simon D. Taylor-Robinson, Editor, Wiley-Blackwell, Chichester, pp.50-57, 2016
- XII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**
Yılmaz Y., Younossi Z.
in: OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editor, Elsevier Science, Oxford/Amsterdam, Pennsylvania, pp.93-107, 2015
- XIII. **Obesity-Associated Nonalcoholic Fatty Liver Disease**
YILMAZ Y., YOUNOSSI Z. M.
in: OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editor, ELSEVIER, Philadelphia, pp.93-107, 2015

Papers Presented at Peer-Reviewed Scientific Conferences

- I. **Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced primary biliary cholangitis**
Manfredi G. F., Ergenc I., Neglia M. C., Sebesta C., Degasperi E., Semmler G., Reiberger T., Cittone M., De Benedittis C., Yapıcı H. B., et al.
European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Netherlands, 7 - 10 May 2025, (Summary Text)
- II. **Obstrüktif Uyku Apne Sendromlu Hastalarda Non-Alkolik Yağlı Karaciğer Hastalığının Değerlendirilmesi**
ÖZYURT S., KEKLİKKIRAN Ç., YILMAZ KARA B., ÖZÇELİK N., GÜMÜŞ A., ŞAHİN Ü., YILMAZ Y.
UASK 2025, Antalya, Turkey, 9 - 12 April 2025, (Summary Text)
- III. **Pruritus and fatigue in patients with metabolic dysfunction associated steatotic liver disease (MASLD):Data from the Global NASH/MASH Registry**
Yılmaz Y., Keklikkiran Ç., Racila A., Stepanova M., Younossi Z.
APASL Congress 2025, Beijing, China, 26 - 31 March 2025, pp.1, (Full Text)
- IV. **Impact of weekend warrior physical activity on all-cause mortality in metabolic dysfunction-associated steatotic liver disease**
Paik J. M., Zelber-Sagi S., Pekas E. J., Wajcman D. I., YILMAZ Y., Alqahtani S. A., El-Kassass M., Gerber L., Younossi Z. M.

- EASL Congress 2025, Amsterdam, Netherlands, 07 February 2025, (Full Text)
- V. **VALIDATION OF AND MECHANISTIC INSIGHTS ON A BILE ACID SIGNATURE OF FIBROSIS PROGRESSION IN METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS**
Smirnova E., Kang J., YILMAZ Y., EREN F., Zhou H., Mirshahi F., Hylemon P., Sanyal A.
The Liver Meeting, California, United States Of America, 15 - 19 November 2024, (Summary Text)
- VI. **THE IMPACT OF SUPERIMPOSED METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES (PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND C (CHC)**
Younossi Z., Buti M., Papatheodoridis G., YILMAZ Y., Yu M., El-Kassas M., Alswat K., Castellanos Fernandez M. I., Eguchi Y., Duseja A., et al.
The Liver Meeting, California, United States Of America, 15 - 19 November 2024, vol.80, (Summary Text)
- VII. **VALIDATION OF MICROBIAL SIGNATURE FOR ADVANCED FIBROSIS IN A GLOBAL MULTI-ETHNIC COHORT OF MASLD**
Smirnova E., YILMAZ Y., EREN F., Muthiah M., Oliveira C., Siddiqui M., Mirshahi F., Hylemon P., Lee J., Sanyal A.
The Liver Meeting, California, United States Of America, 15 - 19 November 2024, (Summary Text)
- VIII. **Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Experience Significant Disease Burden and Stigma**
Younossi Z., YILMAZ Y., Fan J., Zheng M., ALSWAT K. A., ALQAHTANI S., EL-KASSAS M., CASTERA L., FUNUYET-SALAS J., ROMERO-GOMEZ M., et al.
American Diabetes Association (ADA) 2024 Annual Congress, United States Of America, 15 June 2024, vol.73, pp.1414, (Full Text)
- IX. **Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis**
Eruzun H., Bossen L., TURAN D., Ergenç İ., HARPUT Z. N., GÜNEŞ AYDEMİR N., AKDOĞAN KAYHAN M., Yapıcı H. B., Holland-Fischer P., Bach Hansen J., et al.
EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.723, (Full Text)
- X. **Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)**
Younossi Z., YILMAZ Y., Yu M., Isakov V., Fernández M. I. C., Wong V. W., Eguchi Y., Romero-Gómez M., Méndez-Sánchez N., Duseja A. K., et al.
EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.643, (Full Text)
- XI. **Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis**
Francesca Manfredi G., Ergenç İ., Cittone M., Degasperi E., Neglia M. C., Bertetto R., Benedittis C. D., Yapıcı H. B., Pirisi M., Calvaruso V., et al.
EASL Congress 2024, Milan, Italy, 05 June 2024, vol.80, pp.329, (Full Text)
- XII. **Prevalence and predictors of clinically significant pruritus in patients with non-alcoholic fatty liver disease (NAFLD): data from the global NASH registry™ (GNR™)**
Younossi Z. M., YILMAZ Y.
Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.863, (Full Text)
- XIII. **STIGMA IS A PREDICTOR OF IMPAIRMENT OF HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH NAFLD**
Younossi Z. M., YILMAZ Y.
Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.1768-1774, (Full Text)
- XIV. **Stigma in NAFLD and NASH: a global survey of patients and providers**
Younossi Z. M., YILMAZ Y.
International Liver Congress (EASL) 2023, Viyana, Austria, 01 June 2023, vol.78, pp.627-628, (Full Text)
- XV. **THE GLOBAL SURVEY OF DISEASE BURDEN AND STIGMA AMONG PATIENTS WITH NAFLD AND THEIR**

HEALTHCARE PROVIDERS

Younossi Z. M., YILMAZ Y.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.1050-1056, (Full Text)

- XVI. **A GLOBAL SURVEY OF PHYSICIAN KNOWLEDGE ABOUT MANAGEMENT OF CHRONIC HEPATITIS C**
Younossi Z. M., YILMAZ Y.

American Association for the Study of Liver Diseases (AASLD) Meeting 2023, Boston, United States Of America, 10 November 2023, vol.78, pp.671, (Full Text)

- XVII. **Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis**
ERGENÇ İ., YAPICI H., KEKLİKKIRAN Ç., YILMAZ Y.

International Liver Congress (EASL) 2023, Austria, 21 - 24 June 2023, vol.78, pp.389-390, (Full Text)

- XVIII. **NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH SIGNIFICANT IMPAIRMENT OF WORK PRODUCTIVITY: DATA FROM THE GLOBAL NASH REGISTRY™**
Younossi Z., YILMAZ Y., Yu M., Wong V., Fernandez M., Isakov V., Duseja A., Mendez-Sanchez N., Eguchi Y., Bugianesi E., et al.
vol.77, (Summary Text)

- XIX. **Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes**
Pennisi G., Enea M., Falco V., Aithal G., Palaniyappan N., YILMAZ Y., Boursier J., Cassinotto C., Ledinghen V. d., Chan W., et al.
55th A.I.S.F. - Italian Association for the Study of the Liver - Annual Meeting 2023, Milan, Italy, 14 March 2023, vol.55, pp.12-15, (Full Text)

- XX. **REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE**
Lazarus J. V., YILMAZ Y.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 November 2022, vol.76, pp.818-820, (Full Text)

- XXI. **DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY**
Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., Esmat G., Isakov V. A., Wong V. W., Eguchi Y., et al.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 October 2022, vol.76, pp.1049-1051, (Full Text)

- XXII. **CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))**
Younossi Z. M., YILMAZ Y.

Annual Meeting of the Association for the Study of Liver Diseases (AASLD) Meeting 2022, Washington, Kiribati, 04 November 2022, vol.76, pp.287-288, (Full Text)

- XXIII. **Lean non-alcoholic fatty liver disease patients from the global NASH registry**
YILMAZ Y.

EASL, Londrina, Brazil, 22 June 2022, (Full Text)

- XXIV. **Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging**
YILMAZ Y.

EASL, Londrina, Brazil, 22 June 2022, (Full Text)

- XXV. **Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease**
YILMAZ Y.

EASL, Londrina, Brazil, 22 June 2022, (Full Text)

- XXVI. **ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN**

THE ARMOR STUDY OPEN LABEL PART

Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., Sanyal A. J.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 12 November 2021, (Full Text)

- XXVII. Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease**

YILMAZ Y.

French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, France, 07 July 2021, (Full Text)

- XXVIII. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease**

YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., Costentin C., Zheng M., Wong V. W., Elkhashab M., et al.

International Liver Congress (EASL), Roma, Italy, 23 - 26 June 2021, vol.75, pp.257, (Full Text)

- XXIX. The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry**

YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., Mendez-Sanchez N., CHAN W. K., Ashwani S., Brian L., et al.

International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.655, (Full Text)

- XXX. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis**

YILMAZ Y.

International Liver Congress (EASL), Roma, Italy, 23 June 2021, vol.75, pp.259-260, (Full Text)

- XXXI. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?**

Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., Esmat G., George J., Reggiani G. M., Novak K., et al.

International Liver Congress, ELECTR NETWORK, 23 - 26 June 2021, vol.75, (Summary Text)

- XXXII. CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)**

YILMAZ Y.

Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.821-822, (Full Text)

- XXXIII. A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**

YILMAZ Y.

Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.830, (Full Text)

- XXXIV. CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY**

YILMAZ Y.

Digestive Disease Week, United States Of America, 21 May 2021, vol.160, pp.771-772, (Full Text)

- XXXV. RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE WEEK 72 INTERIM SURROGATE EFFICACY ANALYSIS**

Harrison S. A., Ratziu V., Bedossa P., Dufour J., Kruger F., Schattenberg J. M., Francque S. M., Arrese M., George J., Bugianesi E., et al.

AASLD The Liver Meeting, Virginia, United States Of America, 13 - 16 November 2020, pp.23, (Full Text)

- XXXVI. THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)**

YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., Duseja A., Alswat K. A., El Kassas M., Hamid S. S., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72, (Summary Text)

- XXXVII. SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-**

WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS

Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., Fang J., Wong V. W., Alswat K. A., Chan W. K., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72, (Summary Text)

XXXVIII. PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)

Yu M., El Kassas M., Lam B. P., Esmat G., Fernandez M. C., Ferret M. A. B., Papatheodoridis G., Isakov V. A., Duseja A., YILMAZ Y., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72, (Summary Text)

XXXIX. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)

Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., Duseja A., Mendez-Sanchez N., Eguchi Y., George J., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72, (Summary Text)

XL. Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center

YILMAZ Y.

APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Latvia, 4 - 08 March 2020, vol.14, pp.1-470, (Summary Text)

XLI. THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)

YILMAZ Y.

Digestive Disease Week, United States Of America, 23 January 2020, vol.158, pp.1269, (Full Text)

XLII. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, (Full Text)

XLIII. CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.577-578, (Full Text)

XLIV. DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.463-465, (Full Text)

XLV. SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

YILMAZ Y.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.359, (Full Text)

- XLVI. CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE**
- YILMAZ Y.
- Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, United States Of America, 08 November 2019, vol.70, pp.1053-1054, (Full Text)
- XLVII. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS**
- Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.
- Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
- XLVIII. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY**
- Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.
- Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
- XLIX. THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE**
- Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.
- Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)
- L. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**
- Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., Wen Yue L., Hao Yang Z., Xiao Dong W., Wei Jie Y., et al.
- EASL 2019, Paris, France, 14 April 2019, (Summary Text)
- LI. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease**
- Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., Liu W., Zhang H., Wang X., Yuan W., et al.
- International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70, (Summary Text)
- LII. Translating NAFLD AASLD data to local practice**
- YILMAZ Y.
- AASLD TASL Regional Connect Meeting, İstanbul, Turkey, 15 - 16 March 2019, (Summary Text)
- LIII. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Liver Disease(AFLD): The impact of Alcohol Comsumption and Metabolic Syndrome on Mortality**
- Younossi Z., Stepanova M., Ong J., Yilmaz Y., Duseja A., Eguchi Y., Kassas M. E., Fernandez M., George J., Jacobson I., et al.
- THE AASLD LIVER MEETING, South-Carolina, United States Of America, 9 - 13 November 2018, (Summary Text)
- LIV. Noninvazif Fibrozis ve Yağlanması Ölçümü:Fibroscan/CAP**
- YILMAZ Y.
4. Azerbaijan-Türkiye Ortak Hepatoloji Kursu, Baku, Azerbaijan, 06 October 2018, (Summary Text)
- LV. Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality**
- Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., El Kassas M., Fernandez M., George J., Jacobson I. M., et al.
- Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68, (Summary Text)
- LVI. Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients**
- Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., Eguchi Y., Wong V., Negro F., YILMAZ Y., et al.

- Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portugal, 23 - 26 May 2018, vol.102, pp.304-305, (Summary Text)
- LVII. **Transient elastography with controlled attenuation parameterin the assessment of hepatic steatosis and significant liver fibrosisin patients with scleroderma**
Yılmaz Y., Kani H. T., Şahinkaya Y., Mursaloğlu H. H., Aziziy M., İnanç G. N., Direskeneli R. H.
27th Annual Conference of APASL, Dilli, India, 14 - 18 March 2018, vol.12, pp.378, (Summary Text)
- LVIII. **Klinik pratikte transiyent elastografi kullanımı**
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018, (Summary Text)
- LIX. **Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı**
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018, (Summary Text)
- LX. **Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü**
YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaijan, 21 January 2018, (Summary Text)
- LXI. **Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis**
Hasturk B., Yilmaz Y., Eren F.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66, (Summary Text)
- LXII. **Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene**
EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66, (Summary Text)
- LXIII. **Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis**
Hasturk B., Yilmaz Y., Eren F.
European Biotechnology Congress, Dubrovnik, Croatia, 25 - 27 May 2017, vol.256, (Summary Text)
- LXIV. **The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study**
UYGUN A., öztürk k., demirci h., öztuna a., EREN F., KOZAN S., YILMAZ Y., KURT Ö., TÜRKER T., vatansever s., et al.
JOURNAL OF HEPATOLOGY, Amsterdam, Netherlands, 19 - 23 April 2017, vol.66, pp.148, (Summary Text)
- LXV. **Prevalence of Fatty Liver in IBD: ATransient Elastography Study on the Basis of a Controlled AttenuationParameter**
Kani H. T., Demirtas I., Yilmaz Y.
The 5th Annual Meeting of Asian Organization for Crohn's Colitis, Seoul, South Korea, 15 - 17 June 2017, pp.235-236, (Summary Text)
- LXVI. **Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.**
YILMAZ Y., KANI H. T.
5th Annual Meeting of the Asian Organization for Crohn's and Colitis, Seul, South Korea, 15 - 17 June 2017, (Summary Text)
- LXVII. **NAFLD: Yeni ne var?**
YILMAZ Y.
11. Ulusal Hepatoloji Kongresi, Antalya, Turkey, 17 - 21 May 2017, (Summary Text)
- LXVIII. **Hepatit C Tedavilerinin İlaç Etkileşimleri**
YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017, (Summary Text)
- LXIX. **Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi**
YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Turkey, 28 - 29 April 2017, (Summary Text)
- LXX. **NASH'te yeni ne var?**

- YILMAZ Y.
14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Turkey, 5 - 08 April 2017, (Summary Text)
- LXXI. **Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı**
YILMAZ Y.
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 December 2016
- LXXII. **COMPARISON OF DOPPLER ULTRASOUND AND TRANSIENT ELASTOGRAPHY FOR DIAGNOSIS OF SIGNIFICANT FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS**
ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.
ESGAR, 14 - 16 December 2016, (Summary Text)
- LXXIII. **Obezite ve yağlı karaciğer**
YILMAZ Y.
7. Ulusal Obezite Kongresi, İstanbul, Turkey, 8 - 11 December 2016
- LXXIV. **Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu**
DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.
33. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 22 - 27 November 2016, (Summary Text)
- LXXV. **Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma**
UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., KOZAN S., KURT Ö., KİLCİLER A. G., vatansever s., et al.
33.Uluslararası gastronetroloji haftası, Antalya, Turkey, 22 - 27 November 2016, (Summary Text)
- LXXVI. **İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sikliği**
hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.
33.Uluslararası gastronetroloji haftası, Turkey, 22 - 27 November 2016, (Summary Text)
- LXXVII. **Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD**
YILMAZ Y.
APASL Single Topic Conference, İstanbul, Turkey, 22 - 24 September 2016, (Full Text)
- LXXVIII. **MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease**
Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., Atug Ö., İmeryüz N., Akin H.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016, (Summary Text)
- LXXIX. **Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis**
EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- LXXX. **Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis**
ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., ALTUN E., TUNEY D.
European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 June 2016
- LXXXI. **Yağlı Karaciğerde Yeni İlaç Tedavileri**
YILMAZ Y.
Klinik Gastroenteroloji Toplantısı-5, İstanbul, Turkey, 02 June 2016
- LXXXII. **Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmeleri**
YILMAZ Y.
Hepatit B Enfeksiyonu Akademisi, Çanakkale, Turkey, 28 May 2016
- LXXXIII. **Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study**
DURĞAY M., DEYNELİ O., YILMAZ Y.
EASL monothematic conference 2016, Riga, Latvia, 12 - 14 May 2016, (Summary Text)
- LXXXIV. **Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım**
YILMAZ Y.
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Turkey, 17 - 20 March 2016

- LXXXV. **Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var**
YILMAZ Y.
TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015'den Süzülenler, İstanbul, Turkey, 13 January 2016
- LXXXVI. **Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız**
DURĞAY M., DEYNELİ O., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXVII. **NASH Pategenez ve Tedavisinde Yeni Bir Şey Var Mı**
YILMAZ Y.
32.Uluslararası Gastroenteroloji Haftası, Antalya, Turkey, 25 - 29 November 2015
- LXXXVIII. **Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir**
EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., İMERYÜZ N., AKIN H.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- LXXXIX. **Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region**
AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- XC. **Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test**
DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., AYKUT U. E.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- XCI. **Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttıracı protein BPI düzeyi ile ilişkilidir**
EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- XCII. **NAFLD in absence of Metabolic Syndrome**
YILMAZ Y.
FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brazil, 24 November 2015, (Full Text)
- XCIII. **Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması**
ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., HAMZAÖGLU H.
BUHASDER 6.Tepcik Enfeksiyon Günleri Sempozyumu, Muğla, Turkey, 4 - 08 November 2015
- XCIV. **Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir**
Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.43-44
- XCV. **Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı**
DİNÇSES E., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015, vol.26, pp.21
- XCVI. **Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease**
SÜNBÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., YILMAZ Y., AĞIRBAŞLI M. A.
31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 October 2015
- XCVII. **Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?**
Dincses E., YILMAZ Y.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, (Summary Text)
- XCVIII. **Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty**

- liver disease**
- DİNÇSES E., YILMAZ Y.
The AASLD Liver Meeting 2015, San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62, pp.1270
- XCIX. Yeni Antikoagulanlar İşlem öncesi ve sonrası yaklaşım**
YILMAZ Y.
3.Gastrointestinal Endoskopi Günleri, İstanbul, Turkey, 8 - 09 May 2015
- C. Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels**
AKYÜZ Ü., YEŞİL A., YILMAZ Y.
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 May 2015, vol.148, pp.1058
- CI. Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease**
YILMAZ Y.
The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Turkey, 12 - 15 March 2015
- CII. Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit**
YILMAZ Y.
Uludağ İç Hastalıkları Kış Kongresi, Bursa, Turkey, 08 March 2015
- CIII. Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar**
YILMAZ Y.
13. Hepatoloji Sempozyumu, Ankara, Turkey, 17 January 2015
- CIV. Barsak karaciğeri nasıl etkiler**
YILMAZ Y.
31. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 24 - 28 November 2014
- CV. Otoimmün hepatit ilaç hepatotoksitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem**
YILMAZ Y.
A'dan Z'ye Psöriazis Toplantısı, İstanbul, Turkey, 08 November 2014
- CVI. Klinik Araştırma Planlaması**
YILMAZ Y.
11. Ulusal HEBİPA Kongresi, Cyprus (Kktc), 24 - 28 September 2014
- CVII. Alkol Dışı Yağlı Karaciğer Hastalığı**
YILMAZ Y.
1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Turkey, 18 - 19 September 2014
- CVIII. Biodegradable Stentler**
YILMAZ Y.
Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 25 June 2014
- CIX. Fibrokistik Karaciğer Hastalıkları**
YILMAZ Y.
Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Turkey, 13 June 2014
- CX. KC biyopsi Fibroscan uygulamaları**
AYGÜN C., YILMAZ Y.
5. Hepatoloji Okulu, Kocaeli, Turkey, 30 May - 01 June 2014
- CXI. Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi**
YILMAZ Y.
Organ Nakilleri Bilinçlendirme ve Geliştirme Derneği Karaciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Turkey, 24 May 2014
- CXII. Alkol Dışı Yağlı Karaciğer Hastalıkları**
YILMAZ Y.
İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Turkey, 10 May 2014
- CXIII. Nonalkolik yağlı karaciğer Nonalkolik steatohepatit**
YILMAZ Y.

- Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Turkey, 29 March 2014
- CXIV. **Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı**
YILMAZ Y.
Karaciğer Hastalıkları ve Transplantasyonu Güncellemeye Toplantısı, İstanbul, Turkey, 01 March 2014
- CXV. **Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study**
TAŞLI B., YILMAZ Y.
The Asian Pacific Society of Respirology 19th Congress, Balvi, Latvia, 13 - 16 November 2014, vol.19, pp.173-203
- CXVI. **CAP yöntemli Fibroscan ile karaciğer yağlanmasıın kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma**
YILMAZ Y., YESİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013
- CXVII. **Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanmasıın şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder**
YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., İMERYÜZ N.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 October 2013
- CXVIII. **Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease**
Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., Mesci B., Kuru I., Tasan G., YILMAZ Y., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text)
- CXIX. **NAFLD da Metformin Hiç Vermeyelim mi**
YILMAZ Y.
10.Uluslararası Hepato Gastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 25 - 29 September 2013
- CXX. **Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı**
YILMAZ Y.
30. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 11 - 15 September 2013
- CXXI. **HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Ayyildiz T., Colak Y., Senates E., Arabul M., Unsal B., Tuncer I., Dolar E.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58, (Summary Text)
- CXXII. **A BIOMARKER PANEL WITH HIGH SENSITIVITY AND SPECIFICITY FOR NONALCOHOLIC STEATOHEPATITIS IDENTIFIED BY SUPPORT VECTOR MACHINE**
Yilmaz Y., Eren F.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, (Summary Text)
- CXXIII. **HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDÉCAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Eren F., Colak Y., Senates E., Celikel C. A., Imeryuz N.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, (Summary Text)
- CXXIV. **GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Ayyildiz T., Akin H., Colak Y., Ozturk O., Senates E., Tuncer I., Dolar E.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58, (Summary Text)
- CXXV. **Metabolik Sendrom ve NAYK PAtogenezde Yenilikler**
YILMAZ Y.
11. Hepatoloji Sempozyumu, Ankara, Turkey, 18 - 19 January 2013
- CXXVI. **NAFLD patogenezinde yeni ne var Steatoz koruyucu bir mekanizma mıdır**
YILMAZ Y.

29. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 20 - 25 November 2012
- CXXVII. **NASH Tedavisinde Yenilikler**
YILMAZ Y.
9. Ulusal HepatoGastroenteroloji Kongresi, Magosa, Cyprus (Kktc), 26 - 30 September 2012
- CXXVIII. **Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler**
YILMAZ Y.
4. Hepatoloji Okulu, Muğla, Turkey, 25 - 26 May 2012
- CXXIX. **Patogenezde VAT mı önemli SAT mı Günlük yaşamda fruktoz sanıldığı kadar suçlu mu**
YILMAZ Y.
- NAFLD Sempozyumu, Ankara, Turkey, 24 March 2012
- CXXX. **Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis**
Eren F., Imeryuz N., Bas E., Ozkan N., Ozdemir F. T., Yilmaz Y., Celikel C. A., Avsar E., Tozun N. A., Ozer A.
Conference on Digestive Disease Week 2011, Illinois, United States Of America, 7 - 10 May 2011, vol.140,
(Summary Text)
- CXXXI. **SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Yonal O., Kurt R., Eren F., Imeryuz N., Kalayci C., Avsar E.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March -
03 April 2011, (Summary Text)
- CXXXII. **CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Alahdab Y. O., Kurt R., Yonal O., Eren F., Kalayci C., Avsar E.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Germany, 30 March -
03 April 2011, (Summary Text)
- CXXXIII. **PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**
Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., Oral A. Y., Dolar E.
44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22 - 26 April
2009, vol.50, (Summary Text)

Funded Projects

Topcu A., Yıldız S. D., Şehirli Ü. S., Yilmaz Y., Project Supported by Higher Education Institutions, Effect of l-theanine on the morphology of neurons in the striatum in Parkinsonian rats, 2025 - 2026

Activities in Scientific Journals

HELIYON, Assistant Editor/Section Editor, 2023 - Present
Hepatology Forum, Assistant Editor/Section Editor, 2020 - Present
Alimentary Pharmacology & Therapeutics, Committee Member, 2020 - Present

Memberships and Roles in Scientific Organizations

European Association for the Study of the Liver, Member, 2011 - Present

Peer Reviews in Scientific Publications

TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020

GASTROENTEROLOGY RESEARCH AND PRACTICE, SCI Journal, September 2020
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, September 2020
International Journal of Medical Arts, Journal Indexed in ESCI, September 2020
İSTANBUL TIP FAKÜLTESİ DERGİSİ, National Scientific Refreed Journal, August 2020
BIOMED RESEARCH INTERNATIONAL, Journal Indexed in SCI-E, August 2020
ARCHIVES OF MEDICAL RESEARCH, SCI Journal, August 2020
JOURNAL OF DIABETES AND ITS COMPLICATIONS, Journal Indexed in SCI-E, August 2020
HEPATOBILIARY SURGERY AND NUTRITION, SCI Journal, July 2020
JGH Open, Journal Indexed in ESCI, July 2020
DIABETES RESEARCH AND CLINICAL PRACTICE, Journal Indexed in SCI-E, July 2020
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, National Scientific Refreed Journal, July 2020
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, July 2020
Clinical and Molecular Hepatology, Journal Indexed in ESCI, July 2020
CHINESE MEDICAL JOURNAL, Journal Indexed in SCI-E, June 2020
BMC GASTROENTEROLOGY, SCI Journal, June 2020
CANADIAN JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2020
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2020
Exploration of Medicine, Other Indexed Journal, May 2020
LIVER INTERNATIONAL, SCI Journal, March 2020
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, March 2020
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2019
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, June 2019
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, May 2019
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, March 2019
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, February 2019
LIVER INTERNATIONAL, SCI Journal, November 2016
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, SCI Journal, November 2016
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, SCI Journal, October 2016
LIVER INTERNATIONAL, SCI Journal, September 2015
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, July 2015
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015
JOURNAL OF HEPATOLOGY, SCI Journal, June 2015
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, May 2015
TURKISH JOURNAL OF GASTROENTEROLOGY, Journal Indexed in SCI-E, April 2015
LIVER INTERNATIONAL, SCI Journal, August 2014
LIVER INTERNATIONAL, SCI Journal, June 2014
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, SCI Journal, April 2013

Scientific Research / Working Group Memberships

Yağlı Karaciğer Çalışma Grubu, Türk Karaciğer Araştırmaları Derneği, Turkey, <http://www.tasl.org.tr/>, 2020 - Present
The Global Nash Council, Center for Outcomes Research in Liver Diseases, Turkey, <https://www.corld.org/global-nash-council/>, 2018 - Present
The Global Liver Registry, Center For Outcomes Research in Liver Diseases, Turkey, <https://www.corld.org/global-liver-registry/>, 2018 - Present

Metrics

Publication: 474

Citation (WoS): 8525

Citation (Scopus): 16395

H-Index (WoS): 43

H-Index (Scopus): 50

Congress and Symposium Activities

AASLD Annual Meeting, Working Group, Massachusetts, United States Of America, 2019

World Congress of Gastroenterology, Invited Speaker, İstanbul, Turkey, 2019

The NAFLD Summit 2019, Working Group, Sevilla, Spain, 2019

International Conference on Fatty Liver, Working Group, Berlin, Germany, 2019

Working Group, California, United States Of America, 2019

The EASL International Liver Congress, Working Group, Vienna, Austria, 2019

17th Euroasian Congress of Hepato-Gastroenterology and Surgery, Invited Speaker, Split, Croatia, 2019

AASLD TASL Regional Connect Meeting, Invited Speaker, İstanbul, Turkey, 2019

Asian Pacific Association for the Study of the Liver Annual Meeting, Working Group, Manila, Philippines, 2019

Global NASH Council Meeting, Invited Speaker, California, United States Of America, 2018

APASL Single Topic Conference, Invited Speaker, İstanbul, Turkey, 2016

FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment , Invited Speaker, London, United Kingdom, 2015

Awards

Yılmaz Y., 'Dünyanın En Etkili Bilim İnsanları Listesi'nde Türkiye'den Gastroenteroloji alanındaki tek kişi, Plos Biology, July 2020

Eren F., Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2019

Yılmaz Y., Eren F., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2018

Yılmaz Y., Tıp Bilimine Yön Veren 100 Türk, Turkishtime, September 2018

Yılmaz Y., Hayat Bulan Fikirler Proje Destek Ödülü, Gilead, November 2017

Yılmaz Y., En Yüksek Atıf Ödülü, Marmara Üniversitesi, January 2013

Yılmaz Y., Bayındır Tıp Teşvik Ödülü, Bayındır Holding, January 2012

Yılmaz Y., En Fazla Bilimsel Yayın Puanına Sahip Hekim Ödülü, İstanbul İl Sağlık Müdürlüğü, January 2011

Yılmaz Y., Sağlık Bilimleri Alanında En Yüksek Yayın Performans Ödülü, Marmara Üniversitesi, January 2011

Yılmaz Y., Eczacıbaşı Bilim Teşvik Ödülü, Eczacıbaşı Holding, January 2011

Yılmaz Y., Üstün Başarı Ödülü, Marmara Üniversitesi Tıp Fakültesi, January 2010

Yılmaz Y., Yayın Özel Ödülü, Uludağ Üniversitesi, January 2009

Yılmaz Y., Zafer Paykoç Ödülü, Türkiye Hepatoloji Vakfı, January 2007